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ABSTRACT 
Superoxide dismutase 1 (SOD1), located at the cytosol has been postulated to represent 
between 50%-80% of the total SOD activity. The SOD gene is located at 21q22.1.  
Polymorphisms in the genes encoding these enzymes found to be significantly affecting its 
antioxidant role. As oxidative stress is a common pathogenic factor for the dysfunction of 
beta and endothelial cells, polymorphism of SOD genes and oxidative stress has become a 
subject of intense scrutiny for their association with different disease conditions including 
T2DM.  The study was aimed to assess the possible association of SOD1 gene +35A/C 
polymorphism in the pathogenesis of IGR subjects of Bangladeshi origin. A total number of 
54 middle aged (age range: 30-65year) subjects with Impaired Glucose Regulation (IGR) 
were consecutively recruited. Total number of healthy control was 55. IGR was diagnosed 
following WHO guideline. Blood glucose was measured by glucose-oxidase and, 
triglyceride, total cholesterol and HDL-cholesterol by enzymatic colorimetric method. 
Insulin was estimated by enzyme linked immunosorbent assay (ELISA). DNA was 
extracted using QIAGEN Blood DNA Kit which utilizes silica gel DNA separation. 
SOD1 gene +35A/C variant was determined by PCR-RFLP using restriction endonuclease 
HhaI. Data were managed using Statistical Program for Social Science (SPSS). Unpaired 
Student's -`t' test and Chi-squared tests, as appropriate, were performed. The number of 
study subjects of wild AA genotype in control and IGR group was 52 and 54 respectively 
whereas in case of heterozygous (Ht) variant AC genotype the number was 0 and 2 
respectively. SOD1 +35A>C genotype frequency analysis has not shown statistical significant 
association (χ2 = 2.075 and p= 0.150).  For control group, the genotype frequencies of AA and 
AC were 1.0 and 0 respectively. For IGR group, the frequencies were 0.963 and 0.037 
respectively. The data showed that SOD1 gene +35A>C variant is substantially different from 
other population and the polymorphic allele is not associated with insulin secretory defect of 
IGR subjects of Bangladeshi origin. 
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1.   INTRODUCTION 
 
Diabetes is one of the most prevalent and devastating chronic non-communicable diseases 
having serious health, economic and social consequences (IDF 2006). Diabetes mellitus has, 
long been considered as a disease of minor significance to world health, however, it is now 
treated as one of the main threats to human health in the 21" century (Zimmet et al., 2000). In the 
past two decades there has been an explosive increase in the number of people diagnosed with 
diabetes all over the world (Amos et al., 1997; King et al., 1998). Therefore, it may seem strange 
that the developing world, which is associated with hunger and malnutrition, is now experiencing 
an epidemic in Type 2 diabetes.  80% of people with diabetes live in low- and middle-income 
countries (IDF, 2012). Subsequent study estimated the global prevalence of diabetes for all age - 
groups to rise from 2.8% in 2000 to 4.4% in 2030 and also demonstrated the total number of 
diabetics to rise from 171 million in 2000 to 366 million in 2030. It was also shown that about 
two third of the rise in total diabetic patients would be constituted from those of the developing 
countries particularly China, India, Indonesia, Pakistan and Bangladesh (Wild et at., 2004). 
Based on recent community based study, prevalence of diabetes in Bangladesh was found to be 
about 7%.Studies involving rural and urban population revealed the prevalence of diabetes 4% 
and11.4% respectively (Sayeed et at., 2007). 
 
The term diabetes mellitus describes a metabolic disorder of multiple aetiology characterized by 
chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting 
from defects in insulin secretion, insulin action, or both (WHO, 1999; ADA, 2005). The effects 
of diabetes mellitus include long term damage, dysfunction and failure of various organs. 
Diabetes mellitus may present with characteristic symptoms such as thirst, polyuria, blurring of 
vision, and weight loss (WHO, 1999). In its most severe forms, ketoacidosis or a non–ketotic 
hyperosmolar state may develop and lead to stupor, coma and, in absence of effective treatment, 
death (WHO, 1999).  
 
The World Health Organization (WHO) published estimates for the years 2000 and 2030, using 
data from 40 countries but extrapolated to the 191 WHO member states (Wild et al., 2004). 
Diabetes mellitus and its complications contribute significantly to ill health, disability, poor 
quality of life and premature death. Additionally, diabetes mellitus is a contributing factor to 
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several other causes of morbidity and mortality. It also increases the risk of a variety of 
complications including end-stage kidney disease, heart disease, stroke and other vascular 
diseases. According to WHO 346 million people worldwide have diabetes. More than 80% of 
diabetes deaths occur in low and middle-income countries. WHO projects that diabetes death 
will double between 2005 and 2030 (WHO 2011). 
 
1.1 Classification of Diabetes Mellitus 
Diabetes mellitus has long been classified based on its clinical presentation; age of onset and 
special feature, and need for insulin of the individual to control blood glucose. Lawrence (1951) 
was first to introduce the nomenclature type I and type 2 to describe two distinct forms of 
diabetes mellitus. In late seventies the National Institute of Health (NIH), United States of 
America (USA) set up the National Diabetes Data Group (NDDG) that formulates the 
classification and diagnostic criteria. The NDDG introduced the term insulin dependent diabetes 
mellitus (IDDM, Type 1) and noninsulin dependent diabetes mellitus (NIDDM, Type 2) to 
describe two main classes of diabetes (NDDG 1979).  
Table 1.1: Etiological Classification of Diabetes Mellitus (WHO, 1999) 
A. Type 1 (B-cell destruction, usually leading to absolute insulin deficiency)  
 Type I A- Autoimmune mediated type 
 Type 1 B- Non-immune mediated idiopathic type 
B. Type 2 (may range from predominantly insulin resistance with relative insulin deficiency to a 
predominantly secretory defect with or without insulin resistance) 
C. Other Specific Types of Diabetes 
 • Genetic defects of B-cell function 
 • Genetic defects in insulin action 
 • Diseases of the exocrine pancreas 
 • Endocrinopathies 
 • Drug- or chemical-induced 
 • Infections (Congenital rubella, Cytomegalovirus, Others) 
 • Uncommon forms of immune-mediated diabetes 
 • Other Genetic Syndromes Sometimes Associated with Diabetes 
 (Down's syndrome, Friedreich's ataxia, Turner's syndrome, etc) 
D. Gestational diabetes 
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According to the present classification of diabetes four main classes of the disease are type 1, 
type 2, Other Specific types and Gestational Diabetes Mellitus (Table 1.1) (WI 10 1999 and ADA 
1997).The other subclass was protein deficient diabetes mellitus (PDDM). Among the young 
diabetes FCPD was found to be 13% and PDDM 42% (Azad Khan and Ali 1997). The others 
with BMI>19 and diabetes diagnosed at younger age were termed as non insulin dependent 
diabetes mellitus in young (NIDDY). 
1.1.1 Type 1 Diabetes Mellitus 
T1DM is characterized by sudden onset of symptoms, proneness to kitoacidosis and need of 
insulin for survival. The hallmark of the T1DM is pancreatic B cell damage resulting in very low 
to absolute loss of insulin secretion. T1DM mainly occur in children and young adults and 
accounts for about 10% of all diabetic patients (ADA 1997). The incidence of T1DM was found 
to be lowest in Asia (0.1 per 1000,000 in China) and highest in Scandinavia (35.5 per 1000,000 
in Finland). However, there are notable exceptions, for instance the incidence is low in Iceland 
but in Sardinia, Italy the incidence is similar to that of Finland (Karvonen et al., 2000). A report 
from Southern India has shown that these the incidence of T1DM is similar (10.5/1000,000) to 
many European populations (Rainachandran et al., 1986). T1DM is believed to be less prevalent 
in Bangladesh, however, population based studies are still lacking. 
 
T1DM is sub-classified on the basis of type of damage of B-cells; immune mediated type 1 and 
non-immune mediated type 1 (idiopathic type 1, T1DM) (ADA 1997; WHO 1999). Autoimmune 
T1DM is characterized by immune mediated damage, targeted against self antigens, resulting in 
the destruction of the B-cells of the pancreas. A number of autoantibodies have been detected 
against different islet proteins. The rate of B-cell destruction is found to vary widely. It has been 
seen to be usually faster in children and slower in adults. A number of T1DM patients have a 
typical sudden onset of the disease and are ketosis prone. But they lack classical autoantibodies 
directed to islets and/or islet cell proteins and are called idiopathic T1DM. This form of diabetes 
is thought to be most common in African and Asian countries (McLarty et at., 1990). Idiopathic 
T1DM usually occurs to obese teens. Once their blood glucose is controlled by insulin oral 
hypoglycemic agents can be subsequently used before the onset of complete insulin dependence 
as in T1DM. While the exact etiological factor(s) are still unknown, multiple genetic and 
environmental factors are thought to be involved (ADA 1997; WHO 1999). 
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In another in depth study, autoantibody and candidate gene markers were investigated in young 
onset diabetic subjects. T1DM diabetes related antibodies; anti Glutamic acid 
decarboxylase (GAD) antibody and anti 1A2 antibodies were found to be positive around 25% of 
the study subjects (Hassan et al., 2005). INS-VNTR polymorphism did not show any association 
with diabetes. T1DM related auto antibodies were found to be positive in 20% of study subjects 
(Hassan 2006). This suggested diabetes in the young subjects of Bangladesh may represent a 
group of atypical T1DM. 
 
1.1.2 Type 2 Diabetes Mellitus 
Type 2 diabetes mellitus (T2DM) is characterized by the presence of disorders of insulin action 
and/or insulin secretion (Reaven 1988). Both defects are usually present in a 
T2DM patient; however, the primacy of the two factors for the development of diabetes still 
remains to be clearly understood. 
 
In American Indians and South Pacific Islanders, T2DM is the only form of the disorder. 
Overall prevalence of diabetes varies between 15-20%. The highest prevalence of T2DM (50%) 
was found among Pima Indians (49.4% in male and 51.1 % in female) in USA and Nauru (41 %; 
male 40.0% and female 42%) and a very low (0-1.4%; male 0% and female 1.4%) was observed 
among the Mapuches population in Chile and the prevalence was almost nil in rural and peri-
rural population of Papua New Guinea (WHO 1994). In the non-Euripides population the 
prevalence has been shown to vary from <1% in rural Bantu of Tanzania and Mainland China to 
40-50% in Pima Indians (USA) and Nauru (King and Rewers, 1993). Age-standardized 
prevalence of T2DM among native Asians and non-Indian Asians demonstrated an increased 
trend from rural to urban and markedly increased trend among the migrants to the west and 
affluent countries. A similar trend also has been observed among native and migrant Pacific 
Island populations (Coughlan et al., 1997). In multiethnic US society the prevalence of diabetes 
has shown to vary among different ethnic groups; 5% in the Caucasian origin, 10% in African-
Americans, 16% in Cuban origin and 26% in Puerto Ricans (Harris 1991; Flegal et al., 1991). 
Studies involving rural and suburban population in Bangladesh revealed the prevalence of T2D 
to be 4.3% and 4.1% respectively (Sayeed et al., 1997 and 2003). 
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1.1.3  Gestational diabetes 
Gestational diabetes is a type of diabetes that arises during pregnancy (usually during the second 
or third trimester). In some women, it occurs because the body cannot produce enough insulin to 
meet the extra needs of pregnancy. In other women, it may be found during the first trimester of 
pregnancy, and in these women, the condition most likely existed before the pregnancy (Claire 
2008). Gestational diabetes affects up to 5% of all pregnancies (Lancet 2008). Women who are 
overweight or obese are at a higher risk of gestational diabetes. The lifetime risk of developing 
T2DM after gestational diabetes is 30% (Girling et al., 2004). 
 
1.2 prevalence of diabetes mellitus 
 
1.2.1  Global prevalence of diabetes mellitus 
 
Diabetes mellitus (DM) is one of the most common non-communicable diseases (NCDs) 
globally. Diabetes is undoubtedly one of the most challenging health problems in the 21st 
century. The IDF Diabetes Atlas (5th edition) estimates that diabetes caused 4.6 million deaths in 
2011 and 183 million people (50%) with diabetes are undiagnosed (IDF, 2012). The number of 
people with diabetes is increasing in every country. Recent global feature of DM is summarized 
in the table 1.2 
 
1.2.2  Diabetes in Bangladesh  
 
Bangladesh, which is still fighting with communicable diseases, is already overburdened with 
non-communicable diseases. The total number of people with diabetes in Bangladesh is projected 
to rise from 8.4 million in 2011 to 16.8 million in 2030 (IDF, 2012). Several small surveys in 
Bangladesh have shown an increasing trend (Mahtab et al., 1983; Ali et al., 1985; Sayeed et al., 
1985; Sayeed et al., 1995). Over the past 30 years, the increase in prevalence is rising 
exponentially in South Asian region; data suggest a threefold increase (from 2.0 to 7.0%) in the 
urban population of Bangladesh within 5 years (Rahim et al., 2010). Although the rural 
population constitutes >85% of the country's total population, almost 65% of the registered 
diabetic subjects of the Bangladesh Institute of Research and Rehabilitation in Diabetes, 
Endocrine and Metabolic Disorders (BIRDEM) were from urban areas (Sayeed et al., 1993; 
Sayeed et al., 1994). 
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According to the finding of Bangladesh Non-Communicable Diseases (NCD) risk factor survey 
2010, the prevalence of diabetes was 3.9%. Bangladesh Urban Health Survey 2006 suggests that 
in urban area the prevalence is just double (10%) the rural area (5%). In 2010, the IDF estimated 
that 5.7 million (6.1%) and 6.7 million (7.1%) of people living in Bangladesh is suffering from 
diabetes and impaired glucose tolerance (IGT) respectively. By 2030, that number of diabetic 
population is expected to rise to 11.1 million. This explosion in diabetes prevalence will place 
Bangladesh among the top seven countries in terms of the number of people living with diabetes 
in 2030. According to the latest WHO data published in April 2011 diabetes mellitus deaths in 
Bangladesh reached 19,598 or 2.05% of total deaths. The death rate is 23.80 per 100,000 of 
population, which ranked Bangladesh in 109
th
 position in the world (World health rankings, 
2010). 
 
Table 1.2 Prevalence of DM and IGT estimated for the years 2011 and 2030 among  Asian 
population (IDF, 2012): 
 
Country Prevalence (%) adjusted to 
 
 
Numbers of adults 
with diabetes (000s) 
Mean annual 
increment 
(000s) 
 World Population National 
population 
2010 2030  
 2010 2030 2010 2030    
Bangladesh 6.6 7.9 6.1 7.4 5681 10423 237 
Cambodia 5.2 7.5 4.3 5.8 354 724 19 
China 4.2 5.0 4.5 5.8 43157 62553 970 
Dem. Rep of Korea 5.3 6.2 5.7 6.8 943 1256 16 
India 7.8 9.3 7.1 8.6 507568 78036 1813 
Indonesia 4.8 5.9 4.6 6.0 6964 11980 251 
Japan 5.0 5.9 7.3 8.0 7089 6879 -11 
Malaysia 11.6 13.8 10.9 13.4 1846 3245 70 
Myanmar 3.2 4.3 2.8 4.3 922 1755 42 
Nepal 3.9 5.2 3.3 4.2 511 1070 28 
Philippines 7.7 8.9 6.7 7.8 3398 6164 138 
Republic of Korea 7.9 9.0 9.0 11.4 3292 4323 52 
Sri Lanka 10.9 13.5 11.5 14.9 1529 2158 31 
Taiwan 7.5 8.5 5.7 6.8 816 1232 21 
Thailand 7.1 8.4 7.7 9.8 3538 4956 71 
Viet Nam 3.5 4.4 2.9 4.4 1647 3415 88 
  
In Bangladesh, the percentage of diabetes was 5.2% (rural 4.3%, urban 6.9%) in 1994-95 and 
increased to 11.2% (urban) and 6.8% (rural) in 2003-O4 (Mahbubur et al., 2011). A recent 
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population based study showed a significant increase in the prevalence of DM in rural 
Bangladesh from 2.3% to 6.8% over 5 years (Afroza 2011). Table 1.2 summarizes the 2006 
WHO recommendations for the diagnostic criteria for diabetes and intermediate hyperglycaemia.  
 
1.3 Natural history of diabetes mellitus 
Patients with IFG and/Or IGT are now referred to as having ‘prediabetes’ by ADA or IGR by 
WHO (Figure 1.1). IFG and IGF refer to a metabolic state intermediate between normal glucose 
homeostasis and diabetes. They are not interchangeable and represent different abnormalities of 
glucose regulation, one in the fasting state and one postprandial (WHO consultation, 1999). 
 
Stages 
 
 
 
Types 
Normoglycemia Hyper glycemia 
Normal glucose 
tolerance 
Impaired Glucose 
regulation         
IGT and/or IGF 
Diabetes mellitus 
Not insulin 
requiring 
insulin 
requiring 
for control 
insulin 
requiring for 
survival 
Type1 
 Autoimmune 
 Idiopathic 
Type2 
Predominantly           
insulin   
resistance 
Predominantly             
insulin  secretory 
defects 
 
Other specific 
types 
     
Gestational 
diabetes 
     
Figure 1.1: The stages of glucose regulation in different types of DM (Balkan and Eschwege 
2003). 
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All forms of diabetes can pass through a stage of IFG and/or IGT. These categories are a part of 
the natural history of diabetes and not a type of diabetes. That is why they are not included in the 
classiﬁcation of diabetes mellitus by ADA. The additional study, conducted in Denmark was to 
see progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a 
high-risk screening program in general practice. IFG and IGT identiﬁed in general practice 
during a stepwise high-risk screening program for type 2 diabetes has high 1-year progression 
rates to diabetes. The progression rate for IFG was 17.6 and for IGT 18.8 cases per100 persons-
year. When analyzing IGT as two separate categories, i.e. isolated IGT and combined IFG - IGT, 
the progression r were 12.0 and 28.1 diabetes cases per 100 person-years respectively. 
(Rasmusseatesn et al, 2007). Interestingly, there is a tendency for the prevalence rates of IGT to 
decline as those of type 2 diabetes mellitus (DM) rise, perhaps suggesting that areas with a high 
ratio of IGT, Type 2 DM are at an earlier stage of type 2 DM epidemic and thus a particular 
target for preventive strategies (Tony and Cockram, 2003). 
In Taiwan, during the 3-year follow-up, 4.3% of the total population developed diabetes. Of 
those with IFG at baseline, 9.6% progressed to diabetes, but only 2.5% of normoglycemic people 
did so. The multivariate-adjusted odds ratio of developing diabetes was 4.4% for persons with 
IFG compared with those who were normoglycemic at baseline. Other Signiﬁcant predictors’ pf 
progression to diabetes was higher waist-hip ratio (WHR), triglyceride and apolipoprotein B (apo 
B) levels. In these Asian Chinese populations, IFG is a strong predictor of diabetes. The high rate 
of conversion from lFG to diabetes, combined with the previously observed high IFG 
prevalence, suggests future high prevalence rates of diabetes (Chen et al, 2003). 
1.4 Prediabetes 
Two intermediate groups at risk for diabetes are impaired fasting glucose (IFG) and impaired 
glucose tolerance (IGT). IFG and IGT refers a metabolic stage intermediate between normal 
glucose homeostasis and diabetes; these are now termed as prediabetes by ADA and impaired 
glucose regulation by (IGR) WHO. They are not interchangeable and represent different 
abnormalities of glucose regulation, one in fasting state and one postprandial (WHO, 1999). 
According to fasting and post load glucose concentration, at present patients with IGR or 
prediabetes may be stratiﬁed into three subcategories - (1) Isolated IGT; (2) Isolated IFG; and (3) 
Combination of the two ‘IFG-IGT’ (WHO and ADA, 2002). 
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1.4.1  Impaired fasting glucose 
IFG is defined, as fasting plasma glucose between 6.1 and 6.9 mmol/l and 2h plasma glucose 
<7.8 mmol/l. Recently ADA has lowered the cut off value of fasting plasma glucose in IFG from 
6.1 mmol/l to 5.6 mmol/l (ADA, 2005). 
1.4.2 Impaired glucose tolerance 
IGT IS defined as fasting plasma glucose <6.1 mmol/l and 2h plasma glucose between 7.8 and 
11.0 mmol/l (ADA. 2005). Historically the term IGT was first introduced by the National 
diabetes Data Group in 1979 and later re-established by WHO. In this stage blood glucose values 
are higher than the defined normal levels but not high enough to meet the diagnostic criteria for 
diabetes (Rao er al., 2004). 
 
1.4.3 Combined IFG-IGT 
 
Studies involving Bangladeshi as well as other population demonstrated some subjects have 
feature of both IFG and IGT, they are termed as combined IFG-IGT. They have fasting plasma 
glucose 6.1- 6.9 mmol/1 and 2h plasma glucose 7.8 - 11.0 mmol/l (ADA, 2005). In one particular 
study in Denmark the progression of IFG-IGT to diabetes found to be 28% per year (Rasmussen 
et al., 2007). IFG and IGT are asymptomatic and unassociated with any manifested morbidity, 
but their sole significance lies in the fact that they predict future diabetes or cardiovascular 
diseases (Stern and Burke, 2000). 
 
1.4.4 Features of IFG-IGT 
 
The main features of IFG/IGT are: 1) a stage in the natural history of disordered glucose 
metabolism, 2) can lead to any type of diabetes, 3) increased risk of progression to diabetes, 4) 
increased risk of cardiovascular diseases 5) little or no risk of micro vascular diseases, and 6) 
some patient may revert to normoglycemic state (Balkau and Eschwege, 2003). Both IFG and 
IGT are similarly associated with an increased risk of diabetes mellitus. Risk is higher where 
IGT and IFG coexists (Unwin, 2002). 
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1.4.5 Prevalence of prediabetes 
The prevalence of IFG and IGT found to increase with age (Shaw et al., 1999). The prevalence 
of IFG tends to plateau in middle age whereas the prevalence of IGT rises into old age (Unwin, 
2002). IGT is more prevalent than IFG, less than or equal to 50% of people with IFG has IGT 
and 20-30% with IGT also has IFG. The rising prevalence of IGT is assumed to increase from 8.2 
to 9.0% worldwide and 7.1 to 7.8% in Bangladesh from 2003 to 2005 in adults (20-79 yrs age 
groups). The 40-59 age group currently has the greatest number of persons with IGT (Sicree et 
al., 2003). On the other hand, the crude the prevalence of IFG was 12.4% in rural population of 
Bangladesh (Sayeed et al., 2003). 
Table 1.3: Prevalence of IGF and IGT among different population (Abdul-ghani et al., 
2006) 
Population 
Prevalence of 
isolated IGT 
Prevalence of 
isolated IFG 
Prevalence of  IGT 
with IGT 
Prevalence of IFG 
with IGT 
European 8.8 6.9 26.0 31.0 
Australian 8 5.7 24.5 31.3 
Mauritius 13.8 4.2 19.4 44.4 
Pima Indian 10.7 1.9 18.9 56.8 
Swedish 20.3 9.7 27.2 43.9 
Chinese 6.3 0.9 14.7 53.0 
American 11 4.4 26.3 46.9 
Korean 20.1 2.7 13.4 53.0 
 
The prevalence of IFG found to be similar in men and women, but IGT is more frequent in 
women (Shaw et al., 1999). Study involves Dutch population, reported the prevalence of IFG 
and IGT among men to be 9.7% and 13.8%, respectively and in women is 6.1% and 14.6% 
(Corpeleijn et al., 2002). In the AusDiab study, a cross-sectional survey of adults aged 25 years 
and older IGT was present in 10.6% of subjects, being more common in women (11.9% v 9.2% 
in men), and IFG was present in 5.8%, being more prevalent in men (8.1% v 3.4% in women). 
This represents an overall prediabetes prevalence of 16.4% in Australian adults (≥25 years) 
(Dunstan et al., 2002). The prevalence of both IFG and IGT varies considerably based on 
ethnicity, ranging from a low of 6.3% in Chinese (Ko et al., 1998) to a high of 20.3% in a 
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Swedish (Larsson et al., 1998) (Table 1.4). From DECODA (Diabetes Epidemiology: 
Collaborative of Diagnostic criteria in Asia) study, it was found that IGT is more prevalent than 
IFG in all Asian populations studied for all age-2003). The rising prevalence rate of IGT may be 
mainly due to diabetogenic lifestyle factors that lead to obesity and increasing life expectancy. 
 
1.5 Pathogenesis of prediabetes and type 2 diabetes mellitus 
1.5.1 Pathogenesis of prediabetes 
Even though IFG and IGT represent intermediate stages of glucose intolerance, epidemiological 
studies demonstrated that they are likely to be distinct conditions with different pathological 
etiologies (Abdul-ghani et al., 2006). Individuals with isolated IFG manifest mainly of hepatic 
insulin resistance, but have relatively normal skeletal muscle insulin sensitivity. In contrast, those 
with isolated IGT are characterized by more severe muscle insulin resistance and less severe 
hepatic insulin resistance. Differences in insulin secretory abnormalities are also apparent 
between subjects with isolated IFG and isolated IGT whereas those with isolated IFG have 
defects in first phase or early insulin secretion, individuals with isolated IGT have more severe 
defects in second-phase or late insulin secretion. As might be expected, individuals with 
combined IFG-IGT manifest hepatic and muscle insulin resistance as well as impairments in both 
first and second phase insulin secretion. Among subjects with prediabetes, those with combined 
IFG-IGT most closely resemble subjects with T2DM (Weyer et al., 1999; Abdul-Ghani et al., 
2006). 
1.5.2 Pathogenesis of type 2 diabetes mellitus 
The maintenance of normal glucose homeostasis depends on a precisely balanced and dynamic 
interaction between tissue sensitivity to insulin (especially in muscle and liver) and insulin 
secretion (Defronzo, 1988). T2DM is postulated to results from defects in both insulin secretion 
and/or action; both of these defects can have a genetic as well as an acquired component 
(Defronzo, 1998; YKI-Jarvinen, 1994; Ferrannini, 1998). 
1.5.2.1 Insulin resistance 
Insulin resistance believed to the early features in the pathogenesis of T2DM and plausibly 
results from a genetically determined reduction in insulin sensitivity, compounded by exposure 
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to the environmental factors (Olefsky et al., 1982). Important sites of insulin resistance include 
liver and the peripheral tissues, skeletal muscle and fat. In muscle, insulin resistance is 
manifested by decreased glucose uptake and impaired utilization of glucose by non-oxidative 
pathway, primarily glycogen formation, as well as a slight decrease glucose oxidation. In the 
liver, insulin resistance leads to failure of insulin to suppress hepatic glucose production, which 
is fuelled by glycogen breakdown and particularly by gluconeogenesis (Defronzo, 1998). 
1.5.2.2  Defect in insulin secretion 
Defect in insulin secretion assume to mean lower insulin secretion. However, there used to 
prevail some confusion by the findings of higher blood insulin concentrations compatible to or 
even higher than in normal subjects in newly diagnosed T2DM patients (Olefsky et al., 1982; 
Defronzo, 1998). This does not, however, is the indication of normally functioning B cells 
activity since non-diabetic subjects would generate much higher insulin levels if their blood 
glucose would have artificially risen into the diabetic range (Defronzo, 1998; Porte, 1991). Thus 
insulin secretion is already defective at the time of diagnosis and declines steadily thereafter. 
Other feature of B cell dysfunction in the disease includes defective cleavage of the insulin 
precursor, leading to variably increased concentrations of proinsulin and its early ‘split product’ 
derivatives (Gray et al., 1984). 
It is generally accepted that insulin resistance precedes the failure of insulin secretion and 
exuberates this by imposing an increased secretory demand on the B cells. However subtle 
abnormalities in B cell function have been demonstrated early in the course of T2DM (Pratley 
and Weyer, 2001), and even in their first degree relatives (Pimenta et al., 1995) suggesting a 
possible basis for an inherited component of B cell failure, Moreover a prospective study among 
Pima Indians showed that passage from normal to impaired glucose tolerance (IGT) and finally 
to T2DM was accompanied by a progressive decline in B-cell secretory capacity (Weyer et al., 
1999). Finally, extrapolation of the observed rate of B-cell decline observed in the UKIPDS 
study suggests that the loss of B-cell function begins some 10-12 years before diabetes is 
diagnosed (Holman, 1998). 
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1.6 Risk factors for T2DM  
1.6.1 Environmental factors 
A number of environmental factors implicated in the pathogenesis of type 2 varieties, which 
include ethnicity, age, diet, and viral infection and stress (Knip and Akerblom 1999; Dahlquist 
1998). 
Ethnicity: T2DM is up to six times more common in people of South Asian descent and upto 
three times among people of Africa and Africa-Caribbean origin (David, 1999). According to the 
Health Survey for England 2004, doctor diagnosed diabetes is almost four times as prevalent in 
Bangladeshi men, and almost three times as prevalent in Pakistani and Indian men compared 
with men in the general population. Among women, diabetes is more than five times as likely 
among Pakistani women, at least three times as likely in Bangladeshi and Black Caribbean 
women, and two and a half times as likely in Indian women, compared with women in the 
general population. Diabetes found to be generally rare among those aged 16 to 34 years but was 
highest among Indian men (2%), Black African men (1.7%) and Irish women (1.7%) (Elizabeth 
et al, 2006). 
 
Age: Glucose tolerance has been shown to decrease with age (Shimokata et al., 1991). 
However, whether the deterioration is caused by increased chronological age or secondary age 
related factors, such as decreased physical activity, is still to be clearly understood. 
Diet: Diets with high-fat, low-carbohydrate impair the action of insulin on endogenous glucose 
production, glucose oxidation, and probably lipolysis but it does not clearly affect the action of 
insulin on total glucose disposal and tend to enhance the action of insulin on non-oxidative 
glucose disposal (Bisschop et al., 2001). Intake of excessive amounts of saturated fats have lead 
to obesity in individuals, who were found to be more susceptible to develop insulin resistance 
(Lovejoy et al., 2001). 
Obesity: The major environmental risk factor for T2DM is obesity and a sedentary lifestyle 
(Bleich et at., 2007). Thus, the tremendous increase in the rates of T2DM in recent years has 
been attributed, primarily, to the dramatic rise in obesity worldwide (Zimmet et al., 2001). It has 
been estimated that approximately 80% of all new T2DM cases are due to obesity (Lean, 2000). 
This is true for adults and children. In the Pima Indians, 85% of the T2DM children were either 
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overweight or obese (Fagot-Campana et al., 2000). Although excess weight and obesity 
(BMI>25 kg/m2) account for 64% cases of diabetes in men and 74% in women, many cases of 
diabetes occur in lean subjects (Chan et al., 1994; Colditz et al., 1995). 
Sex: Some studies had showed a higher age-adjusted prevalence in women (Eriksson et. al., 
1993), where as some investigators demonstrated male preponderance (Lintott et al., 1992). 
Variation in T2DM prevalence between men and women also has been shown to vary in different 
age group in the same community. 
Stress: Stress has long been suspected as having important effects on the development of 
diabetes. Slawson et al (1963) showed that 80% of a group of 25 adult diabetes patients gave a 
history of antecedent stress mainly in terms of losses, 1-48 months prior to the onset of diabetes. 
These were mostly patient of depression. Metabolic stress may develop due to disproportionate 
amount of free radical productions in diabetes by glucose autoxidation, polyol pathway and non-
enzymatic glycation of proteins. In a study, oxidative stress pathway markers in the diabetic 
patients, type 1 and type 2, was compared to normoglycemic subjects. The increased level of 
glycosylated hemoglobin was observed in the diabetic patients and this increase is directly 
proportional to the blood glucose level (Strain et al. 1991). This suggests the increase in 
oxidative stress due to hyperglycemia. Hypoinsulinaemia in diabetes increases the activity of the 
enzyme fatty acyl coenzyme A oxidase, which initiates R-oxidation of fatty acids , resulting in 
lipid peroxidation, which impairs membrane function changing the activity of membrane-bound 
enzymes and receptors ( Halliwell et al., 1997). 
 
1.6.1.1 Oxidative stress 
Oxidative stress is defined in general as excess formation and/or insufficient removal of highly 
reactive molecules such as reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
(Turko et al.,2001; Maritim et al.,2003). ROS include free radicals such as superoxide (•O2
–
), 
hydroxyl (•OH), peroxyl (•RO₂), hydroperoxyl (•HRO₂-) as well as nonradical species such as 
hydrogen peroxide (H₂O₂), and hydrochlorous acid (HOCl) (Turko et al.,2001; Evans et 
al.,2002). Overproduction of free radicals can cause oxidative damage to biomolecules, (lipids, 
proteins, DNA), eventually leading to many chronic diseases such as atherosclerosis, cancer, 
diabetics, rheumatoid arthritis, post-ischemic perfusion injury, myocardial infarction, 
cardiovascular diseases, chronic inflammation, stroke and septic shock, aging and other 
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degenerative diseases in humans (Freidovich, 1999; Yun-Zhong et al.,2002). Excess vascular 
•O2
– 
production could contribute to hypertension and vasospasm (Huie et al.,1993; Lepoivre et 
al.,1994; Moncada and Higgs, 1993). 
 
 
Figure 1.2: Human diseases where oxidative stress plays direct or indirect role in 
pathophysiology of disease (Uttara et al., 2009) 
1.6.1.2 Mechanism of ROS Generation 
ROS generation is prerequisite of metabolic system in order to interact with organic molecules in 
vivo as interaction of organic molecules with oxygen is energetically unfavorable. In all forms of 
ROS generation, molecular oxygen needs to be activated and cellular system have evolved range 
of metallo-enzymes those facilitates ROS generation upon interaction of redox metals with O2 
using various catalytic pathways. Since free radicals are toxic to cells, under normal 
circumstances, cells have efficient regulating system for O2 and metal ion interaction leading to 
free radicals and ROS generation (Bush, 2000). 
Fe
3+  +  •O2
–
 → Fe2+  +  O2 (Step I) 
Fe
2+
 + H2O2 →Fe
3+
 + OH ‾ + •OH (Step II) Known as Fenton reaction (Roger et al.,1997)     
Combining step I&II 
•O2
–
  +  H2O2 → •OH + HO‾ + O2   
Apart from direct ROS generation, there are different in vivo pathways that contribute 
substantively ROS generation by calcium activation with metallo-enzymes. Calcium is an 
important signaling molecule and it is required for many cellular responses and cell-cell 
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communication. Thus, any disturbance in stimulus and regulation of calcium pathway may 
disrupt the cellular physiology (Angelo et al., 2005). 
1.6.1.3   Sources of oxidative stress in diabetes 
Direct evidence of oxidative stress in diabetes is based on studies that focused on the 
measurement of oxidative stress markers such as plasma and urinary F2-isoprostane as well as 
plasma and tissue levels of nitrotyrosine and •O2
–
 (Vega-Lopez et al.,2004; Oberg et al.,2004; 
Guzik et al.,2000; Ceriello et al.,2001; Guzik et al.,2002 ). There are multiple sources of 
oxidative stress in diabetes including nonenzymatic, enzymatic and mitochondrial pathways. 
 
 
Figure 1.3: Generation of reactive species in diabetes (Johansen et al., 2005). Highlighted in 
gray are some of the most important ROS and RNS in vascular cells. Oxygen is converted to •O2
– 
via 
the activation of enzymatic and nonenzymatic pathways, which is then dismutated to H2O2 by SOD. 
H2O2 can be converted to H2O by catalase or glutathione peroxidase (GSH-Px) or to •OH after 
reaction with Cu or Fe. 
Nonenzymatic sources of oxidative stress originate from the oxidative biochemistry of glucose. 
Hyperglycemia can directly cause increased ROS generation. Glucose can undergo autoxidation 
and generate •OH radicals (Turko et al., 2001). In addition, glucose reacts with proteins in a 
nonenzymatic manner leading to the development of Amadori products followed by formation of 
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AGEs. ROS is generated at multiple steps during this process. In hyperglycemia, there is 
enhanced metabolism of glucose through the polyol (sorbitol) pathway, which also results in 
enhanced production of •O2
–
. 
 
Enzymatic sources of augmented generation of reactive species in diabetes include NOS, 
NAD(P)H oxidase and xanthine oxidase (Guzik et al., 2000; Aliciguzel et al., 2003; Guzik et 
al.,2002). All isoforms of NOS require five cofactors/prosthetic groups such as flavin adenine 
dinucleotide (FAD), flavin mononucleotide (FMN), heme, BH4 and Ca
2+_ 
calmodulin. If NOS 
lacks its substrate L-arginine or one of its cofactors, NOS may produce •O2
– instead of •NO and 
this is referred to as the uncoupled state of NOS (Maritim et al.,2003; Guzik et al.,2000; 
Aliciguzel et al.,2003; Guzik et al.,2002). 
 
NAD(P)H oxidase is a membrane associated enzyme that consists of five subunits and is a major 
source of •O2
– 
production (Guzik et al.,2000 and 2002; Kitada et al.,2003; Etoh et al.,2003). 
Guzik et al. investigated •O2
– 
levels in vascular specimens from diabetic patients and probed 
sources of •O2
– 
using inhibitors of NOS, NAD(P)H oxidase, xanthine oxidase and mitochondrial 
electron transport chain. The study demonstrated that there is enhanced production of •O2
– 
in 
diabetes and this is predominantly mediated by NAD(P)H oxidase. Furthermore, the NOS-
mediated component is greater in patients with diabetes than in patients who do not have 
diabetes (Guzik et al.,2000). NAD(P)H oxidase activity is significantly higher in vascular tissue 
(saphenous vein and internal mammary artery) obtained from diabetic patients (Ergul et al., 
2004). There is plausible evidence that PKC, which is stimulated in diabetes via multiple 
mechanisms, i.e. polyol pathway and Ang II, activates NAD(P)H oxidase (Amiri et al., 2002). 
1.6.1.4    Hyperglycemia-induced mitochondrial superoxide production in diabetes 
Under normal conditions, •O2
– 
is immediately eliminated by natural defense mechanisms. A 
recent study demonstrated that hyperglycemia-induced generation of •O2
– 
at the mitochondrial 
level is the initial trigger of vicious cycle of oxidative stress in diabetes (Nishikawa et al.,2000; 
Brownlee et al.,2001). When endothelial cells are exposed to hyperglycemia at the levels 
relevant to clinical diabetes, there is increased generation of ROS and especially •O2
–
, which 
precedes the activation of four major pathways involved in the development of diabetic 
complications. Nishikawa and colleagues elegantly demonstrated that generation of excess 
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pyruvate via accelerated glycolysis under hyperglycemic conditions floods the mitochondria and 
causes •O2
– 
generation at the level of Complex II in the respiratory chain. What is more 
important is that blockade of •O2
– 
radicals by three different approaches using either a small 
molecule uncoupler of mitochondrial oxidative phosphorylation (CCCP), overexpression of 
uncoupling protein-1 (UCP1) or overexpression of Mn-SOD, prevented changes in NF-κB as 
well as polyol pathway, AGE formation and PKC activity. Based on this information, it has been 
postulated by several groups that mitochondrial •O2
– 
is the initiating snowball that turns 
oxidative stress into an avalanche in diabetes by stimulating more ROS and RNS production via 
downstream activation of NF-κB-mediated cytokine production, PKC and NAD(P)H oxidase 
(Figure 1.4). Thus, inhibition of intracellular free radical formation would provide a causal 
therapy approach in the prevention of oxidative stress and related vascular complications in 
diabetes. 
 
 
Figure 1.4: Current working model for the generation of reactive species and                       
downstream targets in diabetes (Johansen et al., 2005)  
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ROS can stimulate oxidation of low-density lipoprotein (LDL), and ox-LDL, which is not 
recognized by the LDL receptor, can be taken up by scavenger receptors in macrophages 
leading to foam cell formation and atherosclerotic plaques (Boullier et al.,2001).•O2
– 
and H2O2 
stimulate stress-related signaling mechanisms such as NF-κB, p38-MAPK and STAT-JAK 
resulting in VSMC migration and proliferation. In endothelial cells, H₂O₂ mediates apoptosis 
and pathological angiogenesis (Taniyama et al.,2003). Furthermore, •O2
– 
immediately reacts with 
•NO generating cytotoxic ONOO‾ and this reaction itself has several consequences. First, 
ONOO‾ alters function of biomolecules by protein nitration as well as causing lipid peroxidation 
(Turko et al.,2001). 
1.6.2 Genetic factors 
Genetic susceptibility has been implicated in the pathogenesis of both T1DM and T2DM 
diabetes. Tendency of aggregation of T1DM in families has been observed by different 
researchers (Risch et al., 1993; Todd and Farrall 1996). The concordance rate for T1DM among 
monozygotic twins found to be higher between 20-71% compared to that of among dizygotic 
twins (Kyvik et al., 1995; Redondo et al., 1999) suggesting strong genetic role in its 
pathogenesis. The human histocompatibility antigen locus has been found to be in linkage 
disequilibrium in substantial number of T1DM patients (Wolfer al., 1983). Later on variation in 
HLA Class II gene, particularly DQB I and DR4 allele was found to be strongly associated with 
T1DM (Donner et al., 2000; Park et al., 1998). Among other gene loci found to be implicated 
with T1DM are in chromosome 4p15 (IDDM2 and IDDM4) (Sawicki et al., 1997; Hayes et al., 
1998) chromosome 2q13 (IDDM 12), chromosome 2q3-2q34 (IDDM13) (Morahan et al., 1996; 
Larsen et al., 1999), chromosome 6g21(I DDM 15) (Temple et al., 2000). 
Table 1.4:  Several Type 2 Diabetic Susceptibility Genes (Cox et al., 2004) 
 
Gene Locus Variant Estimated RR 
PPARy 3p25 Pro12Ala 1 – 3 
ABCC8 11p15.1 Ser1369Ala 2 – 4 
KCNJ11 11p15.1 Glu23Lys 1 – 2 
CALPN10 2q37.3 A43G 1 – 4 
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PPARy gene is an important regulator of adiposite development and lipid metabolism (Tontonoz 
et al., 1994) has become a potential therapeutic target for the treatment of a diverse array of 
disorders, including T2DM, dyslipidacmia, inflammation and malignancy. One form of the 
PPARy gene (Pro) decreases insulin sensitivity and increases T2DM risk several fold. 
INS gene is located in the IGF2-INS region on short arm of human chromosome 11, locus 
(Powell et al., 2005). The INS gene has a variable number of tandem repeats (VNTR) immediate 
adjacent to the 5' promoter region. 
 
The VNTR polymorphism can be classified into two main groups: small class I alleles (28-44 
repeats) and large class Ill allele (138-159 repeats) at frequencies of about 70 and 30%, 
respectively, and class II alleles of intermediate size are rare (Stead and Jeffreys, 2000). Different 
degrees of association have been reported between the INS VNTR class I/Ill genotype and 
insulin-related traits. The class I allele is associated with increased expression of insulin mRNA 
and insulin levels (Lucassen et al., 1995; Bennett et al., 1996; Le Stunff et al., 2000). The allelic 
variation of VNTR is also associated with the risk of diabetes. It has been found consistently that 
the class I allele increases the risk of TIDM (Julicr et al., 1991; Lucassen et al., 1993). 
 
CTLA-4 (cytotoxic T lymphocyte-antigen 4) gene is located on chromosome 2g31-35, where 
multiple TIDM genes may be located. CTLA-4 gene variants have been associated with TIDM, 
as well as other autoimmune disease. CTLA-4 is a protein that plays a key role in T cell 
activation (Barbara Angel et al., 2009) by recognizing its specific antigen which is presented by 
an antigen presenting cell in a peripheral lymphoid organ, the T cell receives co-stimulatory 
signals to differentiate and proliferate into armed effectors T cells but the principal co-
stimulatory molecule for activation and clonal expansion expressed by T cells are the CD
28
 
receptors. CD
28
 proteins bind to B7 molecules, which are expressed by antigen presenting cells 
(Janeway et al., 2005). 
 
Also, subsequent to T cell activation, the lymphocyte secretes the cytokine interleukin-2 (IL-2), 
which drives proliferation and differentiation of the cell. Activated T cells express a high affinity 
for IL-2 receptors, which binds to the cytokine IL-2. However, it was discovered that when 
CTLA-4 is induced, it decreases IL-2 production (Alegre el al., 1998). The extra cellular domain 
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of CTLA-4 can be fused with the antibody IgG (Freeman el al., 1998). CTLA-4 Ig is a protein 
that is induced to block the production IL-2 and CD
28
/B7 co-stimulation (Alegre et al., 1998). 
 
A meta-analysis was done by Fotini (2005) of 33 studies examining the association of TIDM 
mellitus with polymorphisms in the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene, 
including the A49G (29 comparisons), C (-318) T (three comparisons) and (AT) n niicrosatcllite 
(six comparisons) polymorphisms. 
 
CAPN 10 encodes an intracellular calcium-dependent cysteine protease that is ubiquitously 
expressed (Cox et cil., 2001). A haplotype that was initially allowed to 
T2DM included an intronic A to G mutation at position 43, which appears to be involved in 
CAPN10 transcription. 
1.7 Superoxide dismutases (SODs) 
Mammalian cells have evolved a variety of antioxidant mechanisms to control reactive oxygen 
species (ROS) production and propagation (Fridovich, 1999). The superoxide dismutases (SODs) 
are the first and most important line of antioxidant enzyme defense systems against ROS and 
particularly superoxide anion radicals (Igor et al., 2002). SODs are metalloenzymes that catalyze 
the dismutation of superoxide radical (•O2
–
) into hydrogen peroxide (H2O2).  
Dismutation is a term that refers to a special type of reaction, where two equal but opposite 
reactions occur on two separate molecules. SOD takes two molecules of superoxide, strips the 
extra electron off of one, and places it on the other. So, one ends up with an electron less, 
forming normal oxygen, and the other ends up with an extra electron. The one with the extra 
electron then rapidly picks up two hydrogen ions to form hydrogen peroxide.  
 
Dismutation constitute the first enzymatic step that plays a vital role in the control of cellular 
•O2
–
, production. Of course, hydrogen peroxide is also a dangerous compound, so the cell must 
use the enzyme catalase to detoxify it. Glutathione (GSH) peroxidases (GPXs) are located within 
the mitochondrial matrix and the cytoplasm, and catalase (CAT) found primarily within 
peroxisomes, both belong to the secondary defence mechanism by catalyzing the conversion of 
H2O2 to H2O. GSH reductase (GSR) catalyzes GSH disulphide to reduced GSH, with NADPH as 
the reducing agent. GPX reduces H2O2 or other hydro peroxides using GSH as donor substrate.  
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It follows that SOD1, SOD2, CAT, GPX and GSR represent co-ordinately operating defences 
against ROS propagation (Igor et al.,2002) (Figure 1.5).  
 
Figure 1.5: Schematic representation of the pathways producing ROS and key cellular antioxidant 
enzymatic systems controlling ROS production (Igor et al., 2002). Superoxide radical (•O2
–
), hydrogen 
peroxide (H2O2), nitric oxide (NO•), peroxynitrite (ONOO−), hydroxyl radical (OH•), copper/zinc-
superoxide dismutase (SOD1), manganese-SOD (SOD2), catalase (CAT), glutathione peroxidase (GPX), 
glutathione reductase (GSR), reduced glutathione (GSH), oxidized glutathione (GSSG), NADPH and 
oxidized NADP
+
. 
 
1.7.1  Isoforms of SOD 
At present, three distinct isoforms of SOD have been identified in mammals, and their genomic 
structure, cDNA, and proteins have been described.  
 
1. SOD1, or CuZn-SOD (EC 1.15.1.1), was the first enzyme to be characterized and is a 
copper and zinc-containing homodimer that is found almost exclusively in intracellular 
cytoplasmic spaces.  
2.  SOD2, or Mn-SOD (EC 1.15.1.1), exists as a tetramer and is initially synthesized 
containing a leader peptide, which targets this manganese-containing enzyme exclusively 
to the mitochondrial spaces.  
3. SOD3, or EC-SOD (EC 1.15.1.1), is the most recently characterized SOD, exists as a 
copper and zinc-containing tetramer, and is synthesized containing a signal peptide that 
directs this enzyme exclusively to extracellular spaces.   
      Following figure 1.7 represents genomic organization human SOD isoforms. 
Two isoforms of SOD have Cu and Zn in their catalytic center and are localized to either 
intracellular cytoplasmic compartments (CuZn-SOD or SOD1) or to extracellular elements (EC-
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SOD or SOD3). The copper and zinc ions are bridged by anionic form of imidazole ring of 
histidine. SOD1 has a molecular mass of about 32,000 Da and has been found in the cytoplasm, 
nuclear compartments, and lysosomes of mammalian cells (Chang et al., 1988; Keller et al., 
1991; Crapo et al., 1992; Liou et al., 1993). 
 
 
Figure 1.6: Genomic organization of the three known members of the human SOD enzyme family 
(Igor et al., 2002). SOD3 was placed in the middle in order to demonstrate areas of amino acid sequence 
homology between SOD1 and SOD3. SOD2 has no significant amino acid sequence homology with 
either SOD1 or SOD3. The size of each exon and intron, in base pairs, is shown in association with that 
fragment. Data for this figure was extracted from the following sources: SOD1 (Levanon et al.,1985), 
SOD2 (Ho et al., 1991), and SOD3(Folz and Crapo, 1994). 
 
SOD3 is the most recently discovered and least characterized member of the SOD family. The 
enzyme exists as a homotetramer of molecular weight 135,000 Da with high affinity for heparin 
(Marklund et al., 1982). SOD3 was first detected in human plasma, lymph, ascites, and 
cerebrospinal fluids (Marklund et al., 1982 and 1986). The expression pattern of SOD3 is highly 
restricted to the specific cell type and tissues where its activity can exceed that of SOD1 and 
SOD2. A third isoform of SODs has manganese (Mn) as a cofactor and has been localized to 
mitochondria of aerobic cells (Mn-SOD or SOD2) (Weisiger et al.,1973). It exists as a 
homotetramer with an individual subunit molecular weight of about 23,000 Da (Barra et 
al.,1984). SOD2 has been shown to play a major role in promoting cellular differentiation and 
tumorgenesis (Clair et al.,1994) and in protecting against hyperoxia-induced pulmonary toxicity 
(Wispe et al.,1992). However, the available information related to SOD3 has not been reviewed 
in a comparative perspective along with the other two isoforms. The following figure 1.6 
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represents cellular localization and antioxidant role of SOD1, SOD2 and SOD3 isoforms in 
vascular smooth muscle cells.  
 
1.7.2  Gene Structure and Organization of SOD1 
When SOD1 was isolated for the first time, it was thought to be a copper storage protein (Mann 
and Kleinin, 1938); the catalytic function of SOD1 was discovered in 1969 by McCord and 
Fridovich (McCord and Fridovich, 1969), and it was clear that SOD1 acts as a scavenger of 
superoxide, through a two-step reaction involving reduction and reoxidation of the copper ion in 
its active site (Fridovich et al.,1975).  
 
The human SOD1 gene (Entrez Gene ID 6647) is located on chromosome 21q22.11 (long (q) 
arm of chromosome 21 at position 22.11) and it codes for the monomeric SOD1 polypeptide 
(153 amino acids, molecular weight 16 kDa). More precisely, this gene is located from base pair 
33,031,935 to base pair 33,041,241 with a genomic size of 9307 bp, according to UCSC Genome 
Browser (GRCh37/hg19).  
                                                                                                                                                                  
Figure 1.7: Molecular Location of SOD1 gene on chromosome (http://genome. ucsc.edu/) 
 
The coding region of SOD1 gene consists of five exons interrupted by four introns (Figure 
1.7). Several polymorphisms have been identified in SOD1 gene, mainly distributed in the 
regulatory regions, including promoter UTRs, and introns. With regards to SOD1 mRNA 
splicing, it has been demonstrated that the donor sequence at the first intron presents a T to C 
variant and, consequently, it deviates from the highly conserved 5' GT... AG 3' consensus 
sites. Nevertheless, it has been demonstrated that this unconventional splice junction (5' GC... 
AG 3') is functional (Levanon et al.,1985).The proximal promoter of human SOD1 gene, 
involved in the basal transcription, has been well studied, and it contains not only the TATA 
box, but also a CCAAT box and a GC-rich region, which are recognized by 
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CCAAT/enhancer binding proteins (C/EBPs) and specificity protein 1 (Sp1), respectively 
(Seo et al.,1996).  
 
Figure 1.8: Genomic organization of human SOD1 gene (http://genome.ucsc.edu/). The size of 
exons and introns, in base pairs, is shown in association with each fragment. The 5' flanking 
region is expanded, and the transcription factors, interacting with the corresponding DNA 
regulatory elements, are shown at the bottom. The transcription start site is depicted as an arrow 
at position +1. 
 
Other binding sites for Egr1, AP1, AHR, Nrf2, NF-κB, and TR transcription factors have been 
also identified and verified by functional studies (Figure 1.8). These transcription factors are 
involved in the regulation of SOD1 inducible gene expression under specific extra- and 
intracellular conditions. With regard to the 5' untranslated region (5'UTR), Sherman and 
colleagues (Sherman et al.,1983) demonstrated that SOD1 mRNA posseses various 5' termini, 
which are mapped by both primer extension and Sl mapping. The authors showed that the vast 
majority of the mRNA species has a 5' start site located 23 bp downstream the TATA box 
(TATAAA), while the other mRNA molecules have 5' termini 30, 50, and 65bp upstream from 
the major transcription start site. Consequently, these mRNA species are produced through 
TATA-independent transcription. It would be interesting to perform in-depth investigations about 
the functional relevance of these multiple transcription start sites, mainly to determine the 
potential cell and tissue specificity of the different mRNA species. 
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1.8 Rationale of the present study 
Like many other countries, T2DM constitutes the bulk of the diabetic patients in Bangladesh. 
Series of studies have been undertaken to explore the pathophysiological basis of T2DM and its 
complications in Bangladeshi population. Both insulin secretory dysfunction and insulin 
resistance are found to be present, but compromised insulin secretory capacity is found to be the 
major feature both in nonobese and obese type 2 diabetic subjects of Bangladeshi origin (Junaid, 
2000; Zinnat et al., 2003; Al-Mahmud, 2000; Roy et al., 2007). Some of the established 
polymorphic genetic markers, implicated in the pathogenesis of T2DM, have been studied in this 
population for the understanding of its pathogenic mechanism. These include INS-VNTR, 
CAPN10, and VDR gene common polymorphisms. It understood that T2DM is an extremely 
heterogeneous disorder. Available data on genetic analyses also have shown huge variations 
among different populations. 
Superoxide dismutase 1 (SOD1) is located at the cytosol level (Marchler-Bauer et al., 2007) and 
represents between 50% and 80% of the total SOD activity (Faraci et al.,2004; Fukai et al.,1998). 
Polymorphisms in the genes encoding these enzymes is found to be significantly affecting its 
antioxidant role. As oxidative stress is a common pathogenic factor for the dysfunction of beta 
and endothelial cells, polymorphisms of SOD genes and oxidative stress has become subject of 
intense scrutiny for their association with different disease conditions including T2DM.  
The purpose of this study is to assess the possible association of +35A/C (rs2234694) 
polymorphism in the pathogenesis of IGR in a Bangladeshi population. 
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Hypothesis 
It is understood that T2DM is an extremely heterogeneous disorder. Available data on genetic 
analyses also have shown huge variations among different populations. Oxidative stress is a 
common pathogenic factor for the dysfunction of beta and endothelial cells, polymorphisms of 
SOD genes and oxidative stress is suggested to cause pancreatic B cell damage resulting in its 
insulin secreting dysfunction and thus becomes a subject of intense scrutiny for its association 
with diabetes mellitus. Thus, it was hypothesized that Superoxide dismutase 1 (SOD1) gene +35 
A˃C variant is associated in the pathogenesis of Impaired Glucose Regulation in Bangladeshi 
population. 
 
 
 
 
Objectives 
General objective 
The general objective of the present study was to determine genotype of SOD1 gene +35A>C 
variant in a group of Bangladeshi patient with IGR and explore its role in its pathogenesis. 
Specific objectives  
The specific objectives of the study were to: 
 determine the frequency of SOD1 gene +35A>C polymorphic markers in a group of IGR 
and compare with a group of healthy subjects of Bangladeshi origin 
 explore the relationship between SOD1 gene +35A>C and insulinemic status of the study 
subjects and  
 explore the association, if any, between SOD1 gene +35A>C polymorphic allele and 
anthropometric indices. 
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2. SUBJECTS AND METHODS 
2.1 Place of the study 
The study was conducted in the Department of Physiology and Molecular Biology, 
Bangladesh University of Health Science (BUHS), Dhaka, Bangladesh. 
2.2 Study period 
This study was done during the period of December, 2012 to December, 2013. 
2.3 Study design 
It was a cross-sectional observational study.  
2.4 Subjects 
A total number of 54 middle aged (age range: 30 - 65year) subjects with Impaired Glucose 
Regulation (IGR) was consecutively recruited from Out-patient department of Bangladesh 
Institute of Health Science (BIHS). Impaired Glucose Regulation (IGR) was diagnosed 
following WHO guideline (WHO, 1999). Age and Sex matched healthy subjects (n=55) 
recruited as controls. 
2.5 Recruitment of the subjects  
Subjects consecutively attending the Out-patient department (OPD), BIHS Hospital, an 
enterprise of Bangladesh Diabetic Samity (BADAS) for their regular check up were 
recruited. Healthy control subjects were recruited through personal communication from 
the community.  
Purpose and method of the study were briefed to each individual and informed consent 
(Appendix I) was obtained. A predesigned case record form (Appendix II) was used to 
record age, hereditary, anthropometric and clinical data of the consenting subjects.  
Subjects were requested to report on a prescheduled morning after overnight fasting (8-
10 hours). 
2.6 Selection criteria 
2.6.1 Inclusion criteria 
 Adult subjects with age range 30 to 60 years. 
 Voluntarily agreed to take part in this study by providing informed consent. 
 Age-matched healthy subjects. 
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2.6.2 Exclusion criteria 
 Subjects with co-morbid diseases (infection, stroke, myocardial infarction, major 
surgery, essential hypertension, malabsorption etc.).  
 Subjects with history of medication, which may significantly affect glucose 
metabolism (glucocorticoids, oral contraceptives containing levonorgestral or high-dose 
estrogen, phenytoin, high-dose thiazide diuretics etc.). 
 Pregnant women and lactating mother. 
 Subjects had recent blood transfusion 
2.7 Ethical issues 
Precaution was taken at the time of collection to address the ethical aspect. Consent was 
obtained from the volunteers for the future studies involving molecular analysis in these 
samples. 
It was informed that the data a will only be used for scientific purpose. Identity of the 
individual would not be disclosed. The volunteers under no circumstances would be 
communicated involving any further analysis.  
2.8 Anthropometric measurements   
Height  
Standing height was measured using appropriate scales (Detect-Medic, Detect scales INC, 
USA) without shoes. The patient was positioned fully erect, with the head in the Frankfurt 
plane (with the line connecting the outer canthus of the eyes and the external auditory meatus 
perpendicular to the long axis of the trunk); the back of the head, thoracic spine, buttocks, 
and heels touched the vertical axis of the anthrop meter and the heels were together. Height 
was recorded to the nearest 5 mm.  
Weight  
The balance was placed on a hard flat surface and checked for zero balance before 
measurement. The subjects were in the center of the platform wearing light cloths without 
shoes. Weight was recorded to the nearest 0.5 Kg.  
Calculation of BMI (Kg/m
2
) 
Body mass index (BMI) of the subjects was calculated using following formula: 
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BMI = 2(m)][Height 
   (Kg)Weight 
  
Waist circumference  
Waist circumference was measured to the nearest 0.5 cm with a soft non-elastic measuring 
tape. The tape was snug, but not so tight as to cause skin indentation or pinching. The waist 
circumference was taken to the nearest standing horizontal circumference between the lower 
border of the 12
th
 rib and the highest point of the iliac crest on the mid-axillary line at the end 
of normal expiration.  
Hip circumference (cm)  
Hip circumference was measured at the maximum circumference over the buttocks using soft 
non-elastic measuring tape and reading was taken to the nearest 0.5 cm. 
Calculation of WHR 
Waist to hip ratio (WHR) of the study subjects was calculated as the ratio of waist 
circumference divided by hip circumference. 
2.9 Measurement of blood pressure  
Blood pressure was measured using Barometric Sphygmomanometer. Standard protocol was 
followed to record blood pressure data. Blood pressure was measured in sitting position, with 
calf at the level of the heart. After 10 minutes of rest a second reading was taken and average 
was recorded. Recorded Korotkoff sound I (the first sound) and V (the disappearance of 
sound) denoted the systolic blood pressure (SBP) and diastolic blood pressure (DBP), 
respectively (according to WHO-IHS). 
2.10 Methods 
2.10.1 Collection and storage of blood samples 
Overnight fasting (8-10 hours) blood was collected between 8.00-9.30 am. Venous blood (10 
ml) was obtained by venipuncture following standard procedure. Subjects were then given 
glucose to drink (75 g in 300 ml drinking water). They were requested not to take any food 
and be rested for two hours. The second blood sample was then obtained at two hours.  
A portion of blood (5 ml) sample was taken into a tube containing EDTA (1 mg/ml), mixed 
properly and preserved at -30
o
C for future DNA extraction and subsequent experimentation. 
Fasting and postprandial blood samples were taken into plain tube allowed to clot and serum 
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was separated by centrifugation for 10 min at 3000 rpm using refrigerated centrifuge and 
separated serum was preserved at -25
o
C for further biochemical analyses.  
2.10.2 Biochemical analyses 
The following biochemical parameters were analyzed for the study. 
2.10.2.1 Estimation of glucose  
Glucose was estimated by enzymatic colorimetric (GOD-PAP) method in the Hitachi 704 
Automatic Analyzer, Hitachi Ltd., Tokyo, Japan using reagents of RANDOX Laboratories 
Ltd., UK.  
Principle 
Glucose was determined after enzymatic oxidation in the presence of glucose oxidase. The 
hydrogen peroxide formed reacts with phenol and 4-aminophenazone under catalysis of 
peroxidase to form a red violet quinoneimine dye as indicator (Trinder, 1969). 
 
Reagents 
Contents Initial concentration of solution 
Phosphate Buffer 0.1 mol/L, pH 7.0 
Phenol 11 mol/L 
4-aminophenazone 0.77 mmol/L 
Glucose oxidase 1.5 kU/L 
Peroxidase 1.5 kU/L 
Glucose Standard 5.55 mmol/L (100 mg/dL) 
Uranyl Acetate 0.16% 
 
Materials 
 Micro-centrifuge tube 
 Micropipettes and pipettes 
 Disposable tips 
 Automatic Analyzer (Boehringer Mannheim, 704; HITACHI) 
Glucose + H2O   
Oxidase
eGlucos
2H2O2 + 4-aminophenazone + phenol   PeroxidaseQuinoneimine + 4H2O 
Gluconic acid + H2O2 
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Procedure 
The method determines glucose without deproteinization. The instrument was calibrated 
before estimation. Serum and reagent were taken in specific cup. They were arranged serially 
into the Auto analyzer. The Auto analyzer was programmed for the estimation of glucose and 
allowed to run with following procedure: 
5µl sample and 500µl reagent were mixed and incubated at 37° C for 10 minutes. The 
reaction occurred in reaction cell or cup. The absorbance of the sample and the standard 
against the reagent blank were measured at 500 nm within 60 minutes. 
Calculation of the result 
Optical densities or absorbances were fed into a computer and calculation was done using the 
software program. Values for the unknown samples were calculated by extrapolating the 
absorbance for the standard using following formula. 
 
Glucose concentration (mmol/L) =                     5.55 
 
2.10.2.2 Estimation of total cholesterol  
Total cholesterol was measured by enzymatic endpoint method (Cholesterol 
Oxidase/Peroxidase) method in the Hitachi 704 Automatic Analyzer, Hitachi Ltd., Tokyo, 
Japan using reagents of RANDOX Laboratories Ltd., UK.  
Principle 
The cholesterol is determined after enzymatic hydrolysis and oxidation. The indicator 
quinoneimine is formed from hydrogen peroxide and 4-aminoantiphyrine in the presence of 
phenol and peroxidase (Richmond, 1973). 
Reagents 
Contents Initial concentration of solution 
Phosphate Buffer 0.1 mol/L, pH 7.0 
Phenol 11 mol/L 
4-aminophenazone 0.77 mmol/L 
Glucose oxidase ≥1.5 kU/L 
Peroxidase ≥1.5 kU/L 
Glucose Standard 5.55 mmol/L (100 mg/dL) 
AStandard 
 ASample 
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Materials 
 Micro-centrifuge tube 
 Micropipettes and pipettes 
 Disposable tips 
 Automatic Analyzer (Boehringer Mannheim, 704; HITACHI) 
 
Procedure 
Serum and reagents were taken in specific cup or cell. They were arranged serially. Then ID 
number for each test was entered in the Auto analyzer. 5 µl sample and 500 µl reagent were 
mixed and incubated at 37
0
C for 5 minutes within the Auto lab. The reaction occurred in 
reaction cell or cup. The absorbance of the sample and the standard against the reagent blank 
were measured at 500 nm within 60 minutes. 
Calculation of the result 
Concentration of cholesterol in the sample was calculated by using software program with 
the following formula. 
Cholesterol concentration (mg/dL) =                     concentration of standard.     
 
2.10.2.3 Estimation of triglyceride (TG)  
  
Serum triglyceride was measured by enzymatic colorimetric (GPO-PAP) method in the 
Automatic Analyzer, Hitachi 704, Hitachi Ltd., Tokyo, Japan using reagents of RANDOX 
Laboratories Ltd., UK. 
Principle 
Sample triglycerides incubated with a lipoprotein lipase liberate glycerol and fatty acids. 
Glycerol is converted to glycerol-3-phosphate by glycerol kinase and ATP.Glycerol-3-
phosphate oxidase (GPO) oxidizes glycerol-3-phosphate into dihydroxy acetone phosphate 
and H2O2. In the presence of peroxidase, hydrogen peroxide oxidizes the chromogen-4-
aminoantipyrine and 4-chlorophenol to a violet colored complex. The quinone formed is 
proportional to the amount of triglycerides present in the sample. The principle is based on 
the following reaction system (Fossati and Prencipe, 1982). 
AStandard 
ASample 
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Reagents 
 
Content Concentrations in the Test 
Buffer  
Pipes Buffer 40 mmol/L, pH 7.6 
4-choloro-phenol 5.5 mmol/L 
Magnesium-ions 17.5 mmol/L 
Enzyme Reagent 
4-aminophenazone 
 
ATP 1.0 mmol/L 
Lipases >150 U/ml 
Glycerol-3-phosphate oxidase 1.5 U/ml 
Peroxidase 0.5 U/ml 
Standard 2.29 mmol/L (200 mg/dL) 
Materials 
 Micropipettes and pipettes 
 Disposable tips 
 Auto analyzer (Boehringer Mannheim, 704; HITACHI) 
Procedure 
Serum and reagents were taken in specific cup. They were arranged serially. Then ID number 
for test was entered in the analyzer. Five (5) µl sample and 500 µl reagent were mixed and 
incubated at 37
0
C for 5 minutes within the cell. Reading was taken at 500 nm. 
Calculation of result 
Triglyceride concentration was calculated by following formula: 
 
Triglyceride concentration (mg/dL) =                         Concentration of standard. 
 
Lipase
Glycerol + ATP  Kinase
Glycerol
Glycerol-3-phosphate + O2   
Oxidase
Phosphate
Glycerol
 Peroxidase
glycerol + Fatty acids 
glycerol-3-phosphate + ADP 
dihydroxy acetone phosphate + H2O2 
Triglyceride 
+H2O 
quinoneimine + HCl + 4H2O 2H2O2 + 4-aminophenazone + 4- chlorophenol  
AStandard 
ASample 
35 
 
2.10.2.4 Estimation of high density lipoprotein (HDL) cholesterol 
High density lipoprotein cholesterol (HDL-C) was measured by enzymatic colorimetric 
(CHOD- PAP) method using reagent of RANDOX laboratories Ltd., UK. 
Principle 
HDL (High Density Lipoprotein) is separated from chylomicrons, VLDL (very low density 
lipoprotein) and LDL (Low density lipoprotein) by precipitating reagent (phosphotungstic 
acid-magnesium chloride). After centrifugation, the cholesterol content of HDL fraction, 
which remains in the supernatant, was determined by the enzymatic colorimetric method 
using CHOD- PAP (Friedwald et al., 1972). 
Materials and reagents  
1. Precipitant Buffer 
2. Lipid Controls 
3. Randox aqueous Cholesterol Standard: 200 mg/dL 
4. Reagent solution for cholesterol CHOP-PAP assay.   
5. Pipettes (5 µl –50 µl, 100 µl-1000 µl) and Pipette Tips.  
6. Multi-Channel Pipettes and Pipette Tips: 50-300 µl 
7. Buffer and Reagent Reservoirs 
8. Vortex Mixture 
9. Deionized Water 
10. Microtiter Plate Reader capable of reading absorbency at 450 nm 590 nm 
11. Orbital Microtiter Plate Shaker 
12. Absorbant Paper  
Reagents composition 
Phosphotungstic Acid: 0.55 mmol/L 
Magnesium Chloride: 25 mmol/L  
Standard Preparation 
Dilute Randox aqueous cholesterol standard (200 mg/dl) with deionized water by volume of 
0, 20, 40, 50, and 100 µl. The final volume was 200 µl. 
Assay Procedure 
1. 100 ml serum sample was taken in microcentrifuge tube. 
2. 250 ml HDL-C precipitant was added. 
3. Mixed well and allowed to sit for 10 minutes  
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4. The mix components were vortexed and centrifuged for 15 minutes at 4000 rpm.    
5. 30 µl of each Standard was transferred in first six wells.  
6. 30 µl of clear supernatant was transferred into the other wells.  
7. 250 µl of cholesterol reagent was then added into all the 96 wells quickly using multi-
channel pipettes. 
8. Incubated for 5 minutes at 370C on orbital microtiter plate shaker.   
9. Absorbance was read at 490 nm. 
Calculation of the result 
The HDL-C value of each sample was obtained as follows: 
The net absorbance value for each level, obtained by subtracting the value for the HDLC 
concentration (mg/dl) from the value of individual. The smooth linear curve was drawn and 
the results of unknown samples were calculated using logistic function. 
2.10.2.5 Estimation of low density lipoprotein (LDL) cholesterol  
The LDL-Cholesterol level in serum was calculated by using by Friedewald formula 
(Friedwald et al., 1972). 
Formula  
LDL cholesterol = {Total cholesterol – (HDL cholesterol + x
5
1
Triglyceride)} 
 
2.10.2.6 Estimation of serum glutamate-pyruvate transaminase (SGPT)  
Serum glutamate-pyruvate transaminase (GPT) or alanine aminotransferase (ALT) was 
estimated by UV method using ALT (GPT) opt. kit (RANDOX) (IFCC, 1980).  
Principle 
 
 
 
 
 
 
- oxogluterate + L – alanine L-glutamate + pyruvate 
Pyruvate + NADH + H
+ LDH 
L-lactate + NAD
+ 
SGPT 
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Reagents 
 
         Contents Concentration in the test 
1. Buffer/Substrate 
Tris biffer 
L-alanine 
2. Enzyme/Coenzyme/α-oxoglutarate 
            α-oxoglutarate 
            LD 
            NADH 
 
100 mmol/L, pH 7.5 
0.6 mol/L 
 
15 mmol/L 
≥1.2 U/ml 
0.18 mmol/L 
 
Preparation of Solutions 
1.  Buffer/Substrate: Buffer/Substrate supplied in the kit was used as it is.  
2. Enzyme/Coenzyme/α-oxoglutarate: One vial of Enzyme/Coenzyme/α-oxoglutarate2 was 
reconstituted with the appropriate volume of Buffer/Substrate 1: 
2 ml  for the  20 x  2 ml kit (AL 1200) 
10 ml  for the  20 x  10 ml kit (AL 1205) 
20 ml  for the   5 x  20 ml kit (AL 1268) 
Cat No AL 2360 5 x 100 ml 
One vial of Enzyme/Coenzyme/α-oxoglutarate 2 was reconstituted with a portion of 
Buffer/Substrate 1 and then the entire content was transferred to bottle 1 rinsing bottle 2 
several times.  
Procedure 
Wavelength: 
Cuvette: 
Temperature: 
Measurement: 
340 nm (Hg 334 nm or Hg 365 nm) 
1 cm light path 
25/30/37
o
C 
against air 
Pipetted into cuvette: Macro Micro 
Serum 
Enzyme/Coenzyme/α-oxoglu-tarate 2 
0.2 ml 
2.0 ml 
0.1 ml 
1.0 ml 
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Mixed and initial absorbance was read after 1 minute. Again after 1, 2 and 3 minutes the 
absorbance was read. The absorbance change per minute was noted and if the value is 
between 
0.11 and 0.16 at 340 nm/Hg 340 nm 
0.06 and 0.08 at Hg 365 nm 
Only then the values for the first 2 minutes were used for the calculation. 
Calculation 
To calculate the ALT activity the following formulae was used: 
U/L    =   1746    x    ΔA 340 nm/min 
U/L    =   1780    x    ΔA Hg 334 nm/min 
U/L    =   3235    x    ΔA Hg 365 nm/min 
 
Normal values in serum 
 25
o
C 30
o
C 37
o
C 
Men 
Women 
Up to 22 U/L 
Up to 17 U/L 
Up to 29 U/L  
Up to 22 U/L  
Up to 40 U/L  
Up to 31 U/L 
 
Linearity 
If the absorbance change per minute exceeds  
0.16 at 340 nm/Hg 334 nm 
0.08 at Hg 365 nm 
0.1 ml of sample was diluted with 0.9 ml pf 0.9% NaCl solution and reassessed. The result 
was multiplied by 10. 
2.10.2.7 Estimation of insulin 
Insulin was measured by enzyme linked immunosorbent assay (ELISA) method using kit 
from Linco Research Inc., USA. 
Principle  
This assay is a sandwich ELISA based, sequentially, on: 1) concurrent capture of human 
insulin molecules from samples to the wells of a microtiter plate coated by a pre-titered 
amount of monoclonal anti-human insulin antibodies and the binding of a second biotinylated 
monoclonal mouse anti- antibody to the captured insulin, 2) washing of unbound materials, 
3) binding of horseradish peroxidase (HRP) to the immobilized biotinylated antibodies, 4) 
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washing of free enzyme conjugates, and 5) quantification of immobilized antibody-enzyme 
conjugates by monitoring  horseradish peroxidase (HRP) activities in the presence of the 
substrate 3,3′,5,5′-tetramethylbenzidine (TMB). The enzyme activity is measured 
spectrophotometrically by the increased absorbance at 450 nm after acidification of formed 
products. Since the increase in absorbance is directly proportional to the amount of captured 
human insulin in the unknown sample, the latter can be derived by interpolation from a 
reference curve generated in the same assay with reference standards of known 
concentrations of human insulin. 
Reagents supplied 
Each kit was sufficient to run one 96-well plate and contains the following reagents: 
1. Microtiter plate: Coated with mouse monoclonal anti-human insulin antibodies. 
2. Adhesive plate sealer 
3. 10X concentrate horseradish peroxidase (HRP) wash buffer (250ml). 
4. Standards: Human insulin in buffer 2, 5, 10, 20, 50, 100 and 200 µU/ml; 0.5 ml/bottle, 
ready to use. 
5. Quality Controls 1 and 2: Purified recombinant human insulin in assay buffer, ready to 
use. 
6. Matrix Solution: Heat-treated charcoal stripped off the clot human insulin serum (21 ml), 
ready to use. 
7. Assay Buffer: 0.05 M Phosphosaline, pH 7.4, containing 0.025 M EDTA, 0.08% Sodium 
azide, 1% BSA, 2x9 ml, ready for use. 
8. Human insulin detection antibody: Pre-titered biotinylated monoclonal mouse anti-human 
insulin antibody (2x12 ml), ready to use. 
9. Enzyme solution: Pre-titered streptavidin-horseradish peroxidase. Conjugation Buffer 
(2x12 ml), ready to use. 
10. Substrate: 3,3',5,5'-tetramethylbenzidine (TMB) in buffer (12 ml), ready to use. Minimize 
exposure to light. 
11. Stop solution: 0.3 M HCl (12 ml), ready to use.    
Materials required 
1. Pipettes and pipette tips: 10 µl –20 µl or 20 µl-100 µl 
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2. Multi-channel pipettes: 5~50 µl and 50~300 µl 
3. Reagent reservoirs 
4. Vortex mixture 
5. Deionized water 
6. Microtiter plate reader capable of reading absorbency at 450 nm 590 nm 
7. Orbital microtiter plate shaker 
8. Absorbant paper  
9. Standard refrigerator 
Reagent preparation 
HRP Wash Buffer: Diluted 10X HRP washing buffer concentrate 10 fold by mixing the 
entire content of each bottle with 450 ml deionized water.  
Storage and Stability 
All components of the kit were stored at 2-8º C. Multiple freeze/thaw cycles of the insulin 
standards and Matrix solution were avoided. 
Assay Procedure 
1. The reagents were allowed to come to room temperature. Then each well filled with 
300 µl of diluted HRP wash buffer and incubated at room temperature for 5 minutes. 
Then wash buffer was decanted and the residual amount was removed from all wells by 
inverting the plate and tapping it smartly onto the absorbent towels several times. 
2. The microtitre plate was marked. A layout of the plate for blank, standards, QCs and 
unknown samples were made and recorded on a paper.  
3. 20 µl assay buffer was added to the NSB (Non Specific Binding) wells and each of the 
sample wells. 
4. 20 µl matrix solution was added to the NSB, Standard and Control wells. 
5. 20 µl human insulin standards in the order of ascending concentration was added to the 
appropriate wells. 
6. 20 µl of QC 1 and QC 2 was added to the appropriate wells. 
7. Then 20 µl of unknown samples were added sequentially in wells according to the plate 
layout. 
8. After that 20 µl of detection antibody was added to all wells. All procedures were 
performed within 30 minutes. Plates were covered using plate sealer and incubated at 
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room temperature for 1 hour on an orbital microtitre plate shaker to rotate at moderate 
speed approximately 400 rpm. 
9. At the end of incubation, plate sealer was removed and solutions were decanted. 
Residual solutions were removed by tapping as before.  Each wells was then washed for 
3 times with 300 µl diluted HRP wash buffer. After each wash the plate was tapped on 
a pad of tissue to dry it off.  
10. 100 µl of enzyme solution was added to each well using a multichannel pipette.  Plates 
were covered with sealer and incubated again with moderate shaking at room 
temperature for 30 minutes on microtitre plate shaker. 
11. Then sealer was removed and solutions were decanted from the plate and tapped to 
remove the residual fluid. Then wells were washed for 5 times using 300 µl HRP wash 
buffer per well per wash and after each wash the plate was tapped smartly to remove 
the residual buffer. 
12. 100 µl of substrate solution was added to each well and covered with sealer and 
incubated with moderate shaking at room temperature for 10 minutes on microtitre 
plate shaker. Blue color was formed in the wells of insulin standards with intensity 
proportional to increasing concentrations of insulin. 
13. Finally sealer was removed and 100µl of stop solution was added. Plate was placed on 
a microtitre plate shaker for gentle shaking (400 rpm). 
14. Reading was taken using a microplate reader at 450 nm. 
Calculation of results for unknown samples 
Optical densities of standard and unknown samples were fed in to a computer programme. 
Results of unknown samples were calculated extrapolating standard four parameter logistic 
curves using a Software Kinetical 3. 
2.10.3 Genetic analyses 
Superoxide dismutase 1 (SOD1) genotype was determined by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) method. 
2.10.3.1 DNA extraction 
Extraction of DNA was performed using FavorPrep™ Blood/Cultured Cell Genomic DNA 
Extraction Kit (FAVORGEN®, Taiwan). The kit uses the principal of silica gel DNA 
isolation from whole blood adapted in spin column.  
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Equipment, reagent and accessories 
 Water bath 
 Vortex mixer 
 Centrifuge 
 Microcentrifuge tubes (1.5 ml) 
 Pipette tips at different capacities (10 µl, 20 µl, 100 µl, 200 µl and 1000 µl)  
 Micropipettes (2µl, 20µl, 100µl, 200µl, 100-1000 µl) 
 Absolute ethanol (95-100 %) 
Content of DNA kit 
 Extraction Column (FABG Column) 
 Collection tubes  
 Proteinase K 
 RNase-A solution     
 Lysis Buffer FABG 
 Wash Buffer W1 
 Wash Buffer  
 Elution Buffer  
Preparation of reagents 
Wash buffer W1: 45 ml absolute ethanol (96-100%) was added to 124 ml Wash Buffer W1. 
Wash buffer: 200 ml absolute ethanol (96-100%) was added to 50ml Wash buffer.   
Extraction procedure 
1. Frozen blood was brought to room temperature and made homogenous by brief 
vortexing. Aliquot of blood (200 µl) was transferred into 1.5 ml microcentrifuge tube. 
2. 2 µl of an RNase-A stock solution (100 mg/ml) was added to the sample and incubated 
for 2 minutes at room temperature.  
3. 20 µl FAVORGEN proteinase K and 200 µl Lysis Buffer FABG were added to the 
sample and mixed thoroughly by pulse-vortexing. 
4. Incubated at 60°C for 15 minutes to lyse the sample. During incubation, in order to 
ensure efficient lyses, the sample pulse-vortexed every 5 minutes. 
5. To remove drops from the inside of the lid at the tube briefly centrifuged. 
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6. 200 µl ethanol (96-100%) was added to the sample, and mixed by pulse-vortexing for 
30 seconds. 
7. To remove drops from the inside of the lid at the tube briefly centrifuged. 
8. FABG Mini spin Column was placed to a 2 ml collection tube. The sample mixture 
from the step 7 (including any precipitate) was transferred carefully to the FABG Mini 
spin Column without wetting the rim. Centrifuged at 6000 x g for 1 min and the flow-
through were discarded. Then FABG Mini spin Column was placed on a fresh 2 ml 
collection tube.  
9. FABG Mini spin Column was opened carefully and 500 µl Wash Buffer W1 was added 
without wetting the rim. Centrifuged at 6000 x g for 1 min. The collection tube was 
discarded and the spin column was placed on fresh collection tube. 
10. The FABG Mini spin Column was opened carefully and 750 µl Wash Buffer was added 
without wetting the rim. The cap was screwed carefully and centrifuged at 20000 x g 
for 1 minute. At this stage the column was appeared to be clean. 
11. Centrifuged at 6000 x g for an additional 3 minutes to dry the column. 
12.  The FABG Mini spin Column was placed to Elution tube. 
13.  100 µl Elution Buffer was added to the membrane center of FABG Mini spin column. 
Incubated at room temperature for 15 minutes. Centrifuged at 6000 x g for 2 minutes. 
This elute supposed to contain DNA.  
14. For effective elution, the elution solution must dispend onto the membrane center and 
absorbed completely. Additional 100 µl Elution Buffer was added to the membrane 
center of FABG Mini spin column. Incubated at room temperature for 30 minutes. 
Centrifuged at 6000 x g for 2 minutes. This step elutes any residual DNA that may not 
be eluted in the first elution step.  
15. The DNA fragment was stored at 4⁰C or -20⁰C. 
 
2.10.3.2 Check for DNA yield  
 
DNA yield for each sample was checked by agarose gel (1%) electrophoresis.  
Reagents 
i) Agarose (Invitrogen, USA and  VIOGENE, Taiwan). 
ii) TBE (Tris-borate EDTA) buffer. 
iii) Gel loading buffer (5X concentration). 
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iv) Ethidium bromide (0.5µg /ml). 
Composition of TBE (Tris-borate EDTA) buffer 
 1. Tris Base (54.0 g) 
 2. Boric acid (27.5g) 
 3. EDTA (20 ml of 0.5M) 
Deionized H2O added to make the total volume 1L.  
Procedure 
To prepare agarose gel, appropriate amount of agarose was taken into polypropylene conical 
flasks containing required volume of working tris-borate EDTA (TBE) buffer. Agarose and 
buffer solution were mixed by swirling of the flasks. It was then heated to boiling point in a 
microwave oven with intermittent mixing until agarose was properly boiled. The gel was 
cooled nearer to the gelling point and ethidium bromide (0.5 µg/ml) was added. The gel was 
then poured into horizontal gel mould, combs inserted, and allowed to polymerize. The gel 
was subsequently placed in horizontal electrophoresis tank filled with working TBE buffer.  
To resolve DNA extract, 3 µl of DNA elute was mixed with appropriate amount of loading 
buffer and then the mixer was loaded in agarose gel prepared earlier. The gel was run for at 
medium voltage for required time. DNA presence was visualized under UV light and gel 
image was captured. 
The intensity of the bands obtained for the extracted DNA samples were visually compared 
with that of known concentration of DNA and then the extracted DNA was diluted according 
to the intensity of the bands to make the concentration of all DNA samples between 10-50 
ng/ml, optimum for PCR amplification. 
 
 
 
Figure 2.1: Gel image of DNA electrophoresis to check the extraction yield 
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2.10.3.3 PCR amplification of the SOD1 gene  
The segment of the SOD1 gene containing the polymorphic marker +35A>C was amplified 
by polymerase chain reaction (PCR) and the amplified product was checked by agarose gel 
electrophoresis.  
 
Reagents 
 HotStart Taq Polymerase (QIAGEN, USA) 
 Buffer (QIAGEN, USA) 
 dNTPs (BIONEER, South Korea) 
 Primers (Bioserve, India) 
 Agarose (Invitrogen, USA) 
 Ethidium bromide (Sigma, USA) 
 TBE (Tris-borate EDTA) buffer 
 100 bp DNA ladder (BIONEER, South Korea. Email:sales@bioneer.com) 
PCR of the SOD1 gene 
Polymerase chain reaction (PCR) was carried out in 10 µl reaction volume. PCR product size 
for the primer set is 278bp. PCR was carried out using the following primer set:  
Forward     5′-CTA TCC AGA AAA CAC GGT GGG CC- 3′  
Reverse     5′- TCT ATA TTC AAT CAA ATG CTA CAA AAC -3′ 
PCR primer was selected according to the protocol followed in Flekac et al., 2008. 
PCR condition 
PCR was carried out using HotStar Taq polymerase. Conditions for the amplification 
included initial step of denaturation 95
o
C for 15 minutes followed by 35 cycles of 
denaturation at 94
o
C for 45 seconds, annealing at 55
o
C for 30 seconds and elongation at 72
o
C 
for 30 seconds and finally a step of final elongation at 72
o
C for 10 minutes. PCR assays were 
performed in a DNA Thermal Cycler (Biometra, USA). A negative control (reagent blank), 
which contained all components of the reaction mixture with the exception of the sample 
DNA, was included in every PCR procedure. 
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Concentration of PCR component 
Composition of reaction mix for a PCR of 10 µl contained the following: 
 
 Name of the component              Volume (µl) Concentration 
 DNA                                        3.0                            10-50 ng/ml 
 Buffer                                          1.0                             10x 
 dNTPs                                         0.2                           200 µmol/l 
 Forward Primer (F) 0.5                             100 pmol/µl 
 Reverse Primer (R)                             0.5                             100 pmol/µl 
 HotStart Taq Polymerase                  0.07                               5 U/µl 
 ddH2O                                              4.73 
   Total                                                 10.00 µl 
Evaluation of PCR 
3 µl of PCR product was checked for yield in a 2% agarose gel. The optimum size of the 
product was acertained compairing it with ladder DNA. The amplified DNA was visualized 
using ethidium-bromide under UV light and gel image captured and documented. 
 
 
 
 
 
 
 
 
 
Figure 2.2: Image of gel analysis of SOD1 gene PCR products in a 2% agarose gel     
2.10.3.4 RFLP analysis of SOD1 gene candidate markers 
SOD1 gene candidate polymorphic marker +35A>C was analyzed using site-specific HhaI 
restriction enzyme. Restriction enzyme digestion was performed following standard digestion 
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protocol. Candidate SOD1 gene +35A>C varient disrupt restriction enzyme site and were 
detected by restriction fragment length polymorphism (RFLP) assay. 
Equipments 
 Water bath (JENCONS, USA) 
 Electric balance (Scientech, SA 210, USA) 
 Vortex mixer (Gallenkamp, UK) 
 Refrigerated microcentrifuge (Hettich, USA) 
 Centrifuge (Hanil, South Korea) 
 Microwave oven  
 Gel electrophoresis system (Biometra, USA) 
 Gel documentation system (Bio-Rad, USA) 
 Restriction enzyme kit (Thermo Scientific, USA) 
                                    
 
Figure 2.3:  3% agarose gel image of SOD1 gene +35A>C candidate marker analysis by 
Hha I restriction enzyme digestion. 
Hha I digestion 
SOD1 +35A>C variant polymorphic marker was analyzed using Hha I restriction enzyme. 
The digestion was carried out in a final reaction volume of 10 µl. The enzyme digestion 
protocol was as follows:  
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Hha I restriction enzyme digestion protocol: 
Name of the component              Volume (µl)    
PCR product                                3.0  
10x Buffer Tango                         1.0  
           Restriction enzyme (Hha I)               0.4 (10U/µl) 
 H2O                                              5.6                         
Total reaction volume                    10.00 µl 
Hha I restriction enzyme digestion was carried at 37
o
C for 16 hours in a water bath. Enzyme 
digestion product was resolved in 3% agarose gel and digested product was visualized using 
gel documentation system following ethidium bromide staining.  
The +35A>C polymorphism restricts the Hha I restriction enzyme site as follows: 
 5′…G  C   G↓C…3′ 
3′… C↑G   C  G…5′ 
Fragments produced by the Hha I restriction enzyme digestion of the PCR products was as 
follows: Homozygous wild (AA) genotype 278 bp; heterozygous (Ht) variant (AC) genotype 
78bp, 207 bp and 71 bp. Fragment 71 bp could not be resolved.    
2.10.4 Statistical analyses 
Statistical analysis was performed using Statistical Package for Social Science (SPSS) 
software for Windows version 17 (SPSS Inc., Chicago, Illinois, USA) and AcaStat Software. 
Data were expressed as mean±SD, number (percentage) as appropriate. The statistical 
difference between two groups was assessed by unpaired Student’s‘t’ test. Chi-squared test 
and Z test were also performed in appropriate situation. A two-tailed p value of <0.05 was 
considered statistically significant. 
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3. RESULTS 
Superoxide dismutase 1 (SOD-1) gene +35A/C polymorphism was analyzed in total number 
of 109 unrelated subjects of Bangladeshi origin where 55 were healthy controls and 54 IGR 
subjects.  
3.1 Age, BMI and blood pressure of the study subjects   
3.1.1 Age (years) 
Mean (±SD) age (years) of the control and IGT subjects was 41.56±11.13 and 45.31±9.46 
respectively which did not show statistical significant difference (p=0. 061) (Table 3.1). 
 
3.1.2 Body Mass Index (BMI, Kg/m
2
)  
Mean (±SD) BMI of the control and IGT subjects was 23.44±4.39 and 24.75±4.17 
respectively which did not show any statistical significant difference (p=0. 116) (Table 3.1). 
 
3.1.3 Waist Hip Ratio (WHR) 
Mean (±SD) WHR of the control and IGT subjects was 0.90±0.06 and 0.94±0.08 
respectively which did not show any statistical significant difference (p=0. 010) (Table 3.1). 
Table 3.1: Age, BMI and blood pressure of the study subjects 
Variables Wild AA (n=55) Ht AC (n=54) t/p value 
Age 41.56±11.13 45.31±9.46 -1.892/0.061 
BMI 23.44±4.39 24.75±4.17 -1.583/0.116 
WHR 0.90±0.06 0.94±0.08 -2.610±0.010 
SBP 113.51±14.06 116.66±14.13 -1.161/0.248 
DBP 75.98±9.45 78.43±11.41 -1.218/0.226 
3.1.4 Blood pressure (mmHg)  
3.1.4.1 Systolic Blood Pressure (SBP, mmHg): Mean (±SD) SBP of the control and IGT 
subjects was 113.51±14.06 and 116.66±14.13 respectively which did not show statistical 
significant difference (p=0. 248) (Table 3.1) 
3.1.4.2 Diastolic Blood Pressure (DBP, mmHg): Mean (±SD) of the control and IGT 
subjects was 75.98±9.45 and 78.43±11.41 respectively which did not show statistical 
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significant difference (p=0. 226) (Table 3.1). 
3.2 SOD1 +35A>C Variant Marker Analysis  
3.2.1 SOD1 +35A>C genotype frequencies of the study subjects                                                                                                                                                                                                                  
The number of study subjects of wild (AA) genotype in control and IGR group was 55 
(100%) and 52 (96.3%) respectively and in case of heterozygous (Ht) variant AC genotype 
was 0 and 2 (3.7%) respectively. SOD +35A/C polymorphic wild genotype was 1.00 and 
0.963 in the controls and IGR subjects respectively.  Variant genotype (A/C and C/C) was 0 
and 0.037 respectively in the two groups. These frequency distribution among the groups did 
not exhibit statistical significant association (χ2 = 2.075 and p= 0.150) (Table 3.2). 
In the control the frequency was all ‘A’ allele and in the IGR group ‘A’ allele was 0.981 and 
‘C’ allele was 0.018. This allele frequency distribution among the groups did not show 
statistical significant association (χ2=1.441; p=0.152) (Table 3.2). 
Table 3.2: SOD1 +35A>C genotype and allele frequencies of variants of the     
                  study subjects   
Variables Control (n=55) IGR (n=54) 
Genotype   
Wild  AA [%(n)] 1.0(55) 0.963(52) 
Ht  AC [% (n)] 0 0.037 (2) 
χ2 / p value= 2.075/0.150 
Allele frequency 
A 1. 0 0.981 
C 0 0.18 
χ2 / p value=1.441/0.152 
Data presented as frequency (number of subjects). Chi square test was performed to calculate 
statistical association. A two-tailed p value of <0.05 was considered statistically significant.  
SOD1, Superoxide dismutase; AA,Wild type; AC, Heterozygous variant (Ht); 
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3.3.2 SOD1 +35 A>C genotype frequencies among control and IGR subjects on the 
basis of gender 
The number of male and female subjects in the study was 51 and 58 respectively.  
In male the genotype frequencies for AA and AC were 0.980 and 0.020 respectively and for 
female the frequencies were 0.983  and 0.017 respectively. These frequency distribution did 
not show statistical significant association (χ2 = .008 and p= 0.927) (Table 3.3).  
Table 3.3: SOD1 +35A>C genotype frequencies of the study subjects on the basis of 
gender 
Variables Wild AA  (n) Ht  AC (n) χ2  / p value 
Gender 
Male (n=51) 0.980 (50) 0.020 (1) 
0.008/0.927 
Female (n=58) 0.983 (57) 0.017 (1) 
Data presented as frequency (number). Chi square test was performed to calculate statistical 
association. A two-tailed p value of <0.05 was considered statistically significant. 
 SOD1,Superoxide dismutase; AA,Wild type; AC,Heterozygous variant (Ht).  
3.3 Characteristics of the total study subjects on the basis of SOD1+35A>C genotype 
The data were analyzed according to SOD1+35A>C genotypes AA and AC in total study 
subjects. AA denotes homozygous wild type and AC denotes heterozygous variant type. 
 
3.3.1 Anthropometric characteristics of the total study subjects on the basis of 
SOD1+35A>C genotype 
Age (years) 
Mean (±SD) age (years) is subjects with AA and AC genotype was 43.5±10.5 and 40.5±3.5 
respectively which did not show statistical significant difference (p=0.690) (Table 3.3). 
 
Body Mass Index (BMI, Kg/m
2
)  
Mean (±SD) BMI in subjects with AA and AC genotype was 24.03±4.34 and 26.74±1.26 
respectively which did not show statistical significant difference (p=0.381) (Table 3.3). 
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Waist Hip Ratio (WHR) 
Mean (±SD) WHR in subjects with AA and AC genotype was 0.92±0.07 and 26.74±1.26 
respectively. WHR value in subjects with AA and AC genotype did not show statistical 
significant difference (p=0.381) (Table 3.3). 
Blood pressure (mmHg)  
Systolic Blood Pressure (SBP, mmHg): Mean (±SD) SBP in subjects with AA and AC 
subjects was 115.15±14.17 and 110.00±14.14 respectively which did not show statistical 
significant difference in AA compared to AC genotype subjects (p=0.612) (Table 3.4). 
 
Diastolic Blood Pressure (DBP, mmHg): Mean (±SD) DBP of the AA and AC subjects was 
77.08±10.55 and 82.50±3.54 respectively which did not show statistical significant 
difference in AA compared to AC genotype subjects (p=0.472) (Table 3.4). 
Table 3.4: Anthropometric characteristics of the total study subjects  
               distributed according to their SOD1 +35A>C genotype 
 
Variables Wild AA (n=107) Ht AC (n=2) t/p value 
Age 43.5±10.5  40.5±3.5  0.399/0.690 
BMI 24.03±4.34 26.74±1.26 -0.880/0.381 
WHR 0.92±0.07 0.91±0.09 0.032/0.974 
SBP 115.15±14.17 110.00±14.14 0.509/0.612 
DBP 77.08±10.55 82.50±3.54 0.722/0.472 
Data presented as mean±SD. Statistical comparison between groups was performed using unpaired 
Student’s ‘t’ test. A two-tailed p value of <0.05 was considered statistically significant. 
AA, Wild type; AC, Heterozygous variant (Ht); BMI, Body Mass Index; WHR, waist Hip Ratio; SBP, 
Systolic Blood Pressure; DBP, Diastolic Blood Pressure.  
3.3.2 Glycemic status, lipid profile, liver function status and insulinemic status of the 
total study subjects on the basis of SOD1+35A>C genotype 
Glycemic and insulinemic status  
Fasting glucose (FG, mmol/l): Mean (±SD) FG in subject with AA and AC genotype was 
5.33±.89 and 5.55±1.06 respectively which did not show statistical significant difference 
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(p=0.731) (Table 3.5). 
2h after glucose (2h AG, mmol/l): Mean (±SD) AG in subject with AA and AC was 
6.69±1.76 and 6.35±2.47 respectively which did not show statistical significant difference 
(p=0.786) (Table 3.9). 
Insulin (µIU/ml): Mean (±SD) insulin in subject with AA and AC was 13.80±8.65 and 
22.56±14.24 respectively which did not show statistical significant difference (p=0.163 
(Table 3.5). 
Table 3.5: Biochemical characteristics of the study subjects according to their  
SOD1 35A>C genotype                         
Variables Wild AA (n=107) Ht  AC (n=2) t/p value 
Glycemic status 
FG 5.33±0.89 5.55±1.06 -0.344/0.731 
AG 6.69±1.76 6.35±2.47 0.273/0.786 
Insulinemic status 
Insulin 13.80±8.65 22.56±14.24 -1.405/0.163 
Lipid profile 
TG 159 ±8.19 190.00±88.5 -0.489/0.626 
T chol 188 ±41 146.00±8.51 1.465/0.146 
HDL-c 36.31±7.41 35.00±12.71 0.241/0.810 
LDL-c 119±36 73.00±24.04 1.815/0.072 
 
Data presented as mean±SD. Statistical comparison between groups was performed using unpaired 
Student’s ‘t’ test. A two-tailed p value of <0.05 was considered statistically significant. 
AA, Wild type; AC, Heterozygous  variant (Ht); FG, Fasting glucose (mmol/L); AG, After Glucose (2 
hours after 70g oral glucose load)(mmol/l); TG, Triglyceride ( mg/dl); T chol, Total cholesterol 
(mg/dl); HDL-c, High density lipoprotein cholesterol (mg/dL); LDL-c, Low Density Lipoprotein 
Cholesterol (mg/dl); CREAT,  Serum creatinine (mg/dl); SGPT, Serum glutamate pyruvate 
transaminase (U/L). 
Lipid Profile  
Triglyceride (TG, mg/dl): Mean (±SD) serum TG value in subject with  AA and AC 
genotype was 159±8.19 and 190±88.5 respectively which did not show statistical significant 
difference (p=0.626) (Table 3.5).  
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Total cholesterol (T chol, mg/dl): Mean (±SD) serum T chol value in subject with  AA and 
AC was 188±41 and 146±8.51 respectively. Difference of cholesterol between AA and AC 
subjects was not statistically significant (p=0.146) (Table 3.5).  
High density lipoprotein cholesterol (HDL-c, mg/dl): Mean (±SD) HDL-c value in subject 
with  AA and AC was 36.31±7.41 and 35±12.71 respectively which did not show statistical 
significant difference (p=0.146) (Table 3.5).  
Low density lipoprotein cholesterol (LDL-c, mg/dl): Mean (±SD) LDL-c value in subject 
with  AA and AC was 119±36 and 73±24.01 respectively which did not show statistical 
significant difference (p=0.072) (Table 3.5). 
3.4 Analysis of the association of SOD1 polymorphic variants AA and AC  genotype 
3.4.1 Distribution of the SOD1+35A>C genotype on the basis of BMI 
On the basis of Body Mass Index (BMI, Kg/m
2
) the study population was divided into three 
groups as Normal, Overweight and Obese. In normal group, the frequencies were 1.0 and 0, 
in overweight group, the frequencies were 0.977 and 0.023 respectively, and in obese group, 
the frequencies were 0.955 and 0.045 respectively. These frequency distribution among the 
groups did not show any statistical significant association (χ2 = 1.714 and p= 0.425) (Table 
3.6). 
Table 3.6: SOD1 +35A>C genotype frequencies of the study subjects on the basis of 
BMI 
Variables Wild AA (n=107) Ht AC  (n=2) χ2  / p value 
BMI Group  
Normal 1.0 (42) 0 
1.714/0.425 
Overweight 0.977 (43) 0.023 (1) 
Obese 0.955 (21) 0.045 (1) 
Data presented as frequency (number of subjects). Chi square test was performed to calculate 
statistical association. A two-tailed p value of <0.05 was considered statistically significant.    SOD1, 
Superoxide dismutase; AA, Wild type; AC, Heterozygous variant (Ht);  
BMI, Body Mass Index 
Cut of point of BMI for Asian population: (WHO, 2004) 
Normal range, 18.60 - 24.9; Overweight, 23.00-27.5; Obese, ≥27.5 
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3.4.2 Distribution of the SOD1+35A>C genotype on the basis of blood pressure 
Systolic Blood Pressure (SBP, mmHg) 
On the basis of Systolic Blood Pressure (SBP, mmHg) the study population was divided into 
two groups as Normal and High. For normal group the genotype frequencies of AA and AC 
were 0.978 and 0.022 respectively. For high group, the frequencies were 1.0 and 0 
respectively. These frequency distribution among the groups exhibit statistical highly 
significant association (χ2 = 0.408 and p= 0.523) (Table 3.7). 
Diastolic Blood Pressure (DBP, mmHg)                                                                                  
On the basis of Diastolic Blood Pressure (DBP, mmHg) the study population was divided 
into two groups as Normal and High. For normal group the genotype frequencies of AA and 
AC were 0.989 and 0.011 respectively. For high group the frequencies were 0.947  and 0.053 
respectively.  These frequency distribution among the groups did not show any statistical 
significant association (χ2 = 1.476 and p= 0.224) (Table 3.7). 
 
Table 3.7: SOD1 +35A>C genotype frequencies of the study subjects on the basis of 
blood pressure 
Variables Wild AA  (n=107) Ht  AC (n=2) χ2  / p value 
Systolic Blood Pressure 
Normal 0.978 (88) 0.022 (2) 
0.408/0.523 
High 1.0 (18) 0 
Diastolic Blood Pressure 
Normal 0.989 (88) 0.011 (1) 
1.476/0.224 
High 0.947 (18) 0.053 (1) 
Data presented as frequency (number of subjects). Chi square test was performed to calculate 
statistical association. A two-tailed p value of <0.05 was considered statistically significant. 
SOD1,Superoxide dismutase; AA, Wild type; AC, Heterozygous variant (Ht).  
Normal value of systolic blood pressure 120 mmHg and diastolic blood pressure 80 mmHg. 
3.4.3 Distribution of the SOD1+35A>C genotype on the basis of lipid profile 
Triglyceride (TG, mg/dl) 
On the basis of TG the study population was divided into two groups as Normal and High. 
For normal group the genotype frequencies of AA and AC were 1.0 and 0 respectively. For 
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high group the frequencies were 0.952 and 0.048 respectively.  These frequency distribution 
among the groups did not show any statistical significant association (χ2 = 3.202 and p= 
0.074) (Table 3.8).        
Total cholesterol (mg/dl) 
On the basis of total cholesterol the study population was divided into two groups as normal 
and high. For normal group the genotype frequencies of AA and AC were 0.974 and 0.026  
respectively. For high group the frequencies were 1.0 and 0 respectively.  These frequency 
distribution among the groups did not show any statistical significant association (χ2 = 
0.810a and p= 0.368) (Table 3.8). 
Table 3.8: SOD1 +35A>C genotype frequencies of the study subjects on the basis of 
lipid profile 
Variables Wild AA (n=107) Ht AC (n=2) χ2  / p value 
TG  
Normal 1(67) 0 
3.202/0.074 
High 0.952 (40) 0.048 (2) 
T chol  
Normal 0.974 (76) 0.026 (2) 
0.810/0.368 
High 1.0 (31) 0 
HDL-c  
Normal 1.0 (13) 0 
0.276/0.599 
Low 0.979 (94) 0.021 (2) 
LDL-c  
Normal 0.979 (94) 0.021 (2) 
0.276/0.599 
High 1.0 (13) 0 
 
Data presented as frequency (number of subjects). Chi square test was performed to calculate 
statistical association. A two-tailed p value of <0.05 was considered statistically significant. SOD1, 
Superoxide dismutase; AA, Wild type; AC, Heterozygous variant (Ht). TG, Triglyceride; T chol, Total 
cholesterol; HDL-c, High-density lipoprotein cholesterol; LDL-c,  Low density lipoprotein 
cholesterol.  
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Cut-off values of lipid profile 
TG (50-150 mg/dl); T Cholesterol (150-200 mg/dl); HDL-c (Male: >55; Female: >65 mg/dl) 
LDL-c (Upto150 mg/dl)    
High density lipoprotein cholesterol (HDL-c, mg/d) 
On the basis of HDL-C the study population was divided into two groups as normal and low.  
For normal group the genotype frequencies of AA and AC were 1.0 and 0 respectively. For 
low group the frequencies were 0.979 and 0.021 respectively. These frequency distribution 
among the groups did not show any statistical significant association (χ2 = 0.276 and p= 
0.599) (Table 3.8). 
Low density lipoprotein cholesterol (LDL-c, mg/dl) 
On the basis of LDL-C the study population was divided into two groups as normal and high. 
For normal group the genotype frequencies of AA and AC were 0.979 and 0.021 
respectively. For high group the frequencies were 1.0 and 0 respectively. These frequency 
distribution among the groups did not show any statistical significant association (χ2 = 0.276 
and p= 0.0.599) (Table 3.8).   
 
3.4.4 Distribution of the study subjects on the basis of family history of chronic diseases 
The study subjects were distributed on the basis of the family history of chronic diseases 
such as diabetes mellitus (DM) and hypertension (HTN).  
Table 3.9: Distribution of subjects with SOD1 +35A>C genotype frequencies of the 
study subjects on the basis of family history diabetes mellitus and blood 
pressure 
Variables Wild AA (n=95) Ht AC (n=2) χ2  / p value 
DM family history  
Absent 0.980 (49) 0.020 (1) 
0.002/0.965 
Present 0.979 (46) 0.021 (1) 
HTN family history   
Absent 0.984 (60) 0.016 (1) 
0.145/0.703 
Present 0.972 (35) 0.028 (1) 
Data presented as frequency (number of subjects). Chi square test was performed to calculate 
statistical association. A two-tailed p value of <0.05 was considered statistically significant.  
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SOD1,Superoxide dismutase; AA,Wild type; AC,Heterozygous variant (Ht). 
HTN, Hypertension; DM, Diabetes Mellitus. 
Family history of Diabetes mellitus (DM)  
The genotype frequencies of AA and AC in subjects without family history of diabetes were 
0.980 and 0.020 respectively. In subjects with family history of diabetes, the frequencies 
were 0.979 and 0.021 respectively. These frequency distribution among the groups did not 
show any statistical significant association (χ2 = 0.002a and p= 0.965) (Table 3.9).     
Family history of hypertension (HTN) 
The genotype frequencies of AA and AC in subjects without family history of hypertension 
were 0.984 and 0.016 respectively. In subjects with family history of hypertension, the 
frequencies were 0.972 and 0.028 respectively. These frequency distribution among the 
groups did not show any statistical significant association (χ2 = 0.145 a and p= 0.703) (Table 
3.9).   
3.4.5 Distribution of SOD1 +35A>C genotype on the basis of addictive habits 
History of Smoking 
SOD1+35A>C genotype AA and AC frequency in subjects without smoking habit were 
0.968 and 0.032 respectively and in subjects with smoking habit the frequencies were 1.0 
and 0 respectively. These frequency distribution among the groups did not show any 
statistical significant association (χ2 = 1.055/ and p= 0.304) (Table 3.10). 
Table 3.10: SOD1 +35A>C genotype frequencies of the study subjects on the basis of 
smoking and tobacco abuse 
Variables Wild AA (n=92) Ht AC (n=2) χ2  / p value 
Smoking 
 
Absent 0.968 (60) 0.032 (2) 
1.055/0.304 
Present 1.0 (32) 0 
Tobacco 
 
Absent 0.976 (83) 0.024 (2) 
0.216/0.642 
Present 1.0 (9) 0 
Data presented as frequency (number of subjects). Chi square test was performed to calculate    
statistical association. A two-tailed p value of <0.05 was considered statistically significant.  
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SOD1,Superoxide dismutase; AA,Wild type; AC,Heterozygous variant (Ht). 
History of Tobacco abuse 
SOD1+35A>C genotype  AA and AC frequencies in subjects without history of tobacco 
abuse were 0.976 and 0.024 respectively. In those with history of tobacco abuse the 
frequencies were 1.0 and 0 respectively. These frequency distribution among the groups did 
not show any statistical significant association (χ2 = 0.216 and p= 0.642) (Table 3.10). 
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4. DISCUSSION 
 
Free radicals has been hypothesized to cause oxidative damage of biomolecules, (lipids, 
proteins, DNA), eventually leading to many chronic diseases such as atherosclerosis, cancer, 
diabetes, rheumatoid arthritis, cardiovascular diseases, chronic inflammation, stroke and 
septic shock, aging and other degenerative diseases in humans (Freidovich, 1999; Yun-Zhong 
et al.,  2002). Reactive oxygen species (ROS) has been shown to act as a common mediator 
of pathophysiological effects of hyperglycaemia, which is hypothesized to lead to increased 
mitochondrial ROS formation (Brownlee et al., 2001). A recent study demonstrated that 
hyperglycemia-induced generation of superoxide radical (•O₂-) at the mitochondrial level is 
the initial trigger of a vicious cycle of oxidative stress in type 2 diabetes (T2DM) (Nishikawa 
et al., 2000; Brownlee et al., 2001). 
Mammalian cells have evolved with a variety of antioxidant mechanisms to control ROS 
production and propagation (Fridovich 1999). The superoxide dismutases (SODs) are the first 
and most important line of antioxidant enzyme defense systems against the ROS and 
particularly superoxide anion radicals (Igor et al., 2002). SODs are metalloenzymes that 
catalyze the dismutation of superoxide radical (•O₂-) into hydrogen peroxide (H₂O₂). 
Superoxide dismutase 1 (SOD1) is located at the cytosol (Marchler-Bauer et al., 2007) and 
represents between 50% and 80% of the total SOD activity (Faraci et al., 2004; Fukai et al., 
1998). SOD1-gene has five exons and four introns and the +35A/C polymorphism (21q22.1) 
is located adjacent to the splicing point being related to the SOD1-activity – AA-genotype 
having the higher SOD1-activity (Flekac et al., 2008). 
 
It is understood that single nucleotide polymorphisms (SNPs) in DNA sequence are present at 
1% or more within a population. The frequency of each SNP is highly variable between 
different populations within a single species. Polymorphism in the gene encoding the enzyme 
has been found to significantly affect its antioxidant role. As oxidative stress is a common 
pathogenic mechanism for the beta and endothelial cell damage, polymorphisms of SOD1 
gene has become a subject of intense scrutiny for their association with metabolic disorder 
like diabetes. 
 
A number of gene variants have been identified in the SOD1 gene (Flakar et al., 2008). These 
variants have been found to be linked with functional difference of the enzyme. SOD1 gene 
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35A>C polymorphism adjacent to spicing site and reported to show lowering of its 
phenotypic activity (Flakar et al., 2008) 
Attempt was made to compare this genotype pattern with different ethnic population. Ghattas 
and Abo-Elmatty (2012) in their study demonstrated that healthy control subjects had wild 
‘AA’ genotype 71.3% of the Egyptian population and in healthy Czech population control 
subjects had 27%, 50% and 25% AA, AC and CC genotype respectively. This finding 
suggest that SOD1 gene +35A>C polymorphic genotype are substantially different in 
Bangladeshi subjects from those of other ethnic background. However, it may be pointed out 
that only a relatively small number of subjects was included in study of both the healthy 
controls and impaired glucose regulation (IGR) group. Thus the finding of the present study 
needs to be substantiated by recruiting adequate number of subjects to achieve the optimum 
statistical power.   
The main aim of the study was to determine whether genetic varieties of superoxide 
dismutase1 (SOD1) gene +35A>C (21q22.1) is associated with IGR patients of Bangladeshi 
origin. It has been mentioned that all the controls had wild ‘AA’ genotype and only two out 
of 54 IGR subjects were heterozygous. Owing to this fact that variant genotype sub-classified 
and analyzed the study variables for wild and variant genotype were inappropriate. It has 
been already mentioned about the smaller number of study subjects and inclusion of 
appropriate number of subjects will allow analyzing the target variable on the basis of wild 
and variant genotype and explore its relationship in the pathogenesis of insulin secretory 
capacity and ultimately understand the pathophysiology of diabetic  
In the present study a total of 109 unrelated subjects (55 healthy controls and 54 IGR) were 
screened for glycemic status and SOD1 gene common polymorphic variants were 
investigated to explore its association with IGR and their biochemical traits. Among the 
subjects 51 (46.8%) were male and 58 (53.2%) were female. 
It was observed that the all control subject had ‘AA’ genotype. The trend was similar in the 
IGR subjects as well. Out of 54 IGR subjects 52 had wild ‘AA’ genotype and the rest 2 (two) 
were heterozygous. The frequencies of the SOD1 gene +35A>C polymorphism did not show 
any association with IGR. The wild genotype was predominantly present in this study subject 
[100% is control and 96.3% is IGR]. This observation is supported by previous study carried 
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out on T2DM.  In that study 96.9% of TDM subject had wild ‘AA’ genotype. It appears that 
the candidate SOD1 +35A>C polymorphism is relatively lower in frequency. 
 
SOD1 +35A>C genotype frequency analysis did not shown statistical significant association 
(χ2 = 2.075 and p= 0.150).  The number of study subjects of wild AA genotype in control and 
IGR group was 52 and 54 respectively where in case of heterozygous (Ht) variant AC 
genotype the number was 0 and 2 respectively. For control group the genotype frequencies of 
AA and AC were 1.0 and 0 respectively. For IGR group, the frequencies were 0.963 and 
0.037 respectively. Frequencies of the SOD1 +35A>C allele were 0.514 and 0 for A and C 
alleles respectively in the control group. In the IGR group the frequencies were  0.986 and 
0.5 respectively. This allele frequency distribution among the groups have not shown 
statistically significant association (χ2=1.441; p=0.152) 
 
Thus it may be concluded that SOD1 gene +35A>C variant is substantially different from 
other population and the polymorphic allele is not associated with insulin secretory defect of 
IGR subjects of Bangladeshi origin.  
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5. CONCLUSION 
The observations made in the present study indicate that SOD1 +35A>C polymorphism may 
not be associated with the pathogenesis of Impaired Glucose Regulation (IGR) and insulin 
secretory mechanism in Bangladeshi subjects. 
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6. LIMITATIONS AND RECOMMENDATIONS 
Limitations 
 In the present study a small number of subjects was recruited. 
 Measurement of blood superoxide dismutase level was not done; this would have 
strengthened the data substantially. 
 Measurement of Insulin secretory capacity (HOMA%B) and insulin sensitivity 
(HOMA%S) were not done; this would have given the opportunity to explore its 
relationship with marker allele. 
 
Recommendations 
 The study needs to be expanded involving adequate number of patients to provide 
optimum statistical significance.  
 Further study with larger sample size should be designed to explore the effect of SOD1 
gene +35A>C polymorphism with insulin secretory capacity of the IGR subjects of 
Bangladeshi origin. 
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Appendix I 
ইম্পেয়ারড গু্লম্প াস ররগুম্পেশন 
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Appendix II 
 
Data collection Form 
Dept. of Physiology and Molecular Biology 
BIHS 
 
Project title: Superoxide Dismutase 1 (SOD-1) gene +35A/C (intron3/exon3)    
                       Polymorphism in Bangladeshi type 2 diabetic subjects 
 
Code no:                                                              Date:                                Gender: M/F 
 
Name:  Age 
(yr) 
 
 
Address & 
Phone no. 
 
 
Anthropometry: 
Height (cm) Weight(kg) Waist 
circum(cm) 
Hip circum 
(cm) 
Mid-arm 
Circum(cm) 
Body fat 
mass (%) 
      
 
Blood pressure (mmHg): 
  
Marital Status: 
 
 
Residence : 
 
Religion : 
 
 
 
Education: 
 
 
Occupation: 
  Student  Professionals Office job  Skilled worker Unskilled 
worker  
1 2 3 4 5 
  
Annual income: 
<5000 <10,000 10,000-20,000 20,000-30,000 >30,000 
1 2 3 4 5 
Systolic blood pressure  Diastolic blood pressure  
Married 1 unmarried 2 
Rural  Semiurban Urban  
        1       2        3 
Muslim  Hindu  Christian  Buddhist  Other  
     1     2      3     4     5 
Illiterate  Primary  Secondary  Graduate  Above  
      1       2       3       4      5 
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Obstetrical history: 
Menopause   yes 1 No  0 
Menstrual cycle  Regular  1 Irregular  2 
OCP Yes  1 No  0 
 
Physical activity: 
 
Type of activity: 
 
 
Duration of exercise: 
 
Habits:  
Smoking : Present: 
 
 
Previous : 
 
 
 
 
Tobacco leaf chewing/ using powder: 
Previous user  No  0 Yes  1 Duration   
Present user  No  0 Yes  1 Duration   
 
Betel leaf chewing : 
Present user  No  0 Yes  1 Duration   
Previous user  No  0 Yes  1 Duration   
  
Tobacco powder sniffing: 
Present user  No  0 Yes  1 Duration   
Previous user  No  0 Yes  1 Duration   
 
History of beverage drinking: 
Alcohol :  
Present user  No  0 Yes  1 Duration   
Previous user  No  0 Yes  1 Duration   
 
Tea / coffee: 
Present user  No  0 Yes  1 Duration   
Previous user  No  0 Yes  1 Duration   
 
Soft drinks (habitual=regular basis): 
Present user  No  0 Yes  1 Duration   
Previous user  No  0 Yes  1 Duration   
 
Energy drinks: 
Present user  No  0 Yes  1 Duration   
Previous user  No  0 Yes  1 Duration   
Physical work 1 Sedentary work 2 
walking Free hand  Gym  
1 2 3 
<1 hr 1 >1 hr 2 
No  0 Yes  1 Duration   No. of 
sticks  
 
No  0 Yes  1 duration  No. of 
sticks 
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Time of supper: 
 
Consumption of meat per week: 
once 1 twice 2 thrice 3 more 4 
 
Medical history: 
Present: 
 
Previous: 
 
Family history of chronic diseases: 
Diabetes: 
Father  Mother  Brother  Sister  M uncle Aunt P uncle aunt M GP P GP 
      1     2      3    4          5           6    7     8 
 
Hypertension: 
Father  Mother  Brother  Sister  M uncle Aunt P uncle aunt M GP P GP 
      1     2      3    4          5           6    7     8 
 
Heart disease: 
Father  Mother  Brother  Sister  M uncle Aunt P uncle aunt M GP P GP 
      1     2      3    4          5           6    7     8 
 
Stroke:  
Father  Mother  Brother  Sister  M uncle Aunt P uncle aunt M GP P GP 
      1     2      3    4          5           6    7     8 
 
 
 
 
